Data / Research funding / Orphan Drug
Orphan Drug: 7,530 NIH awards ($11B) to 1,062 organizations
7,530 NIH awards ($11B) in the NIH spending category Orphan Drug, to 1,062 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 7,530 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $472,070,715 | December 1, 2024 | November 30, 2025 | CURRIER, JUDITH S. | reporter.nih.gov |
| HIV Vaccines Clinical Trials Network Leadership and Operations Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $244,071,463 | June 29, 2006 | November 30, 2027 | COREY, LAWRENCE | reporter.nih.gov |
| HIV Vaccine Trials Network Laboratory Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $177,480,054 | June 29, 2006 | November 30, 2027 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| COG NCTN Year 12 BIQSFP Progress Report | NIH | National Cancer Institute | 2021 to 2025 | $141,250,012 | April 11, 2014 | February 28, 2026 | HAWKINS, DOUGLAS S. | reporter.nih.gov |
| IMPAACT Leadership Group | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $77,468,129 | December 1, 2024 | November 30, 2027 | NACHMAN, SHARON A | reporter.nih.gov |
| NCI Early Career Cancer Clinical Investigator Award | NIH | National Cancer Institute | 2021 to 2025 | $65,560,307 | March 10, 1997 | November 30, 2026 | EBERT, BENJAMIN LEVINE | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $61,029,344 | September 30, 2019 | March 31, 2027 | URDAHL, KEVIN | reporter.nih.gov |
| ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration, Cycle 2 (ALLFTD2) | NIH | National Institute on Aging | 2021 to 2025 | $56,766,232 | September 15, 2019 | August 31, 2030 | BOEVE, BRADLEY F | reporter.nih.gov |
| NRG Oncology NCORP Research Base-BIQSFP | NIH | National Cancer Institute | 2021 to 2025 | $54,340,726 | July 11, 2025 | July 31, 2026 | BRUNER, DEBORAH WATKINS | reporter.nih.gov |
| Access for All in ALS (ALL ALS) West Clinical Coordinating Center | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $51,203,440 | September 25, 2023 | June 30, 2027 | BOWSER, ROBERT P | reporter.nih.gov |
| Abramson Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $48,027,008 | January 15, 1997 | May 31, 2026 | VONDERHEIDE, ROBERT H. | reporter.nih.gov |
| Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $44,959,734 | August 13, 2025 | November 30, 2026 | KOTLOFF, KAREN L. | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $38,435,039 | September 30, 2019 | September 29, 2026 | FORTUNE, SARAH | reporter.nih.gov |
| Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $35,184,139 | August 1, 2021 | July 31, 2026 | COLER, RHEA | reporter.nih.gov |
| Children's Oncology Group | NIH | National Cancer Institute | 2023 to 2025 | $31,354,180 | March 1, 2023 | February 28, 2026 | ALONZO, TODD A | reporter.nih.gov |
| The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) | NIH | National Institute on Aging | 2024 to 2025 | $30,281,212 | August 15, 2024 | July 31, 2029 | BOXER, ADAM L. | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $29,642,385 | September 12, 1997 | November 30, 2025 | RATHMELL, WENDY KIMRYN | reporter.nih.gov |
| FOLLOW-UP AND EXTENDED FOLLOW-UP OF PARTICIPANTS | NIH | National Cancer Institute | 2021 to 2025 | $29,487,084 | April 6, 2018 | September 15, 2026 | PORRAS, CAROLINA | reporter.nih.gov |
| Task V15: Development of Assays and Reagents for mpox Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $28,751,383 | September 1, 2022 | April 30, 2026 | RUDGE, THOMAS | reporter.nih.gov |
| An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $27,895,551 | September 25, 2023 | August 31, 2027 | PAGANONI, SABRINA | reporter.nih.gov |
| Children's Oncology Group NCI Community Oncology Research Program (NCORP) Research Base grant | NIH | National Cancer Institute | 2021 to 2025 | $27,607,459 | June 1, 2025 | July 31, 2026 | ROTH, MICHAEL E. | reporter.nih.gov |
| Childhood Cancer Survivorship Study | NIH | National Cancer Institute | 2021 to 2025 | $27,522,831 | July 20, 1993 | November 30, 2026 | ARMSTRONG, GREGORY | reporter.nih.gov |
| A non-viral CRISPR-mediated genome editing delivery platform as a potential therapy for neurogenetic diseases | NIH | National Center for Advancing Translational Sciences | 2023 to 2025 | $26,526,303 | September 20, 2023 | July 31, 2027 | JIANG, YONG-HUI | reporter.nih.gov |
| University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,477,809 | February 1, 2007 | November 30, 2027 | ERON, JOSEPH J | reporter.nih.gov |
| Center without Walls for Imaging Proteinopathies with PET | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $24,457,384 | September 24, 2019 | July 31, 2029 | MACH, ROBERT H | reporter.nih.gov |
| Vaccine and Treatment Evaluation Units | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $22,981,366 | December 11, 2019 | November 30, 2026 | ROUPHAEL, NADINE GEORGES | reporter.nih.gov |
| CCSG - Administrative Supplement - ECIA | NIH | National Cancer Institute | 2021 to 2025 | $22,920,176 | September 1, 1997 | March 31, 2029 | ODUNSI, KUNLE | reporter.nih.gov |
| MANUFACTURE OF CLINICAL GRADE EPSTEIN-BARR VIRUS VACCINE | NIH | National Cancer Institute | 2023 to 2025 | $22,579,077 | September 22, 2025 | September 21, 2027 | reporter.nih.gov | |
| UCLA AIDS Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,546,764 | February 1, 2007 | November 30, 2027 | LANDOVITZ, RAPHAEL J | reporter.nih.gov |
| Vaccine and Treatment Evaluation Unit at Saint Louis University | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,219,564 | December 11, 2019 | November 30, 2026 | HOFT, DANIEL F. | reporter.nih.gov |
| West Virginia IDeA Network of Biomedical Research Excellence (WV-INBRE) | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $20,261,619 | September 30, 2001 | July 31, 2029 | JOSHI, TRUPTI | reporter.nih.gov |
| Louisiana Biomedical Research Network | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $18,867,890 | September 25, 2001 | April 30, 2030 | KOUSOULAS, KONSTANTIN G | reporter.nih.gov |
| Pediatric Brain Tumor Consortium A multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumors | NIH | National Cancer Institute | 2021 to 2025 | $18,653,803 | April 1, 1999 | March 31, 2026 | ONAR-THOMAS, ARZU | reporter.nih.gov |
| An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 | $18,136,504 | September 28, 2022 | August 31, 2025 | PAGANONI, SABRINA | reporter.nih.gov |
| Guide RNA manufacturing capabilities for platform in vivo base editing therapies for metabolic liver diseases | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $17,556,074 | August 1, 2023 | July 31, 2028 | PERANTEAU, WILLIAM H. | reporter.nih.gov |
| The Indiana University-Ohio State University Maternal and Pediatric Precision in Therapeutics Data, Model, Knowledge, and Research Coordination Center (IU-OSU MPRINT DMKRCC) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $17,481,052 | September 10, 2021 | July 31, 2027 | QUINNEY, SARA K | reporter.nih.gov |
| Emory-CDC CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,972,899 | December 1, 2024 | November 30, 2027 | KELLEY, COLLEEN F | reporter.nih.gov |
| Center for Viral Systems Biology (CViSB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,438,330 | February 1, 2018 | January 31, 2028 | ANDERSEN, KRISTIAN GRAUGAARD | reporter.nih.gov |
| C3PO - The Candidate Clinical Correlate of Prognostic Outcome for TB Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $15,575,398 | July 1, 2024 | May 31, 2026 | NAHID, PAYAM | reporter.nih.gov |
| Therapeutic Editing to Lower PrP in Prion Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $15,507,691 | May 17, 2023 | April 30, 2026 | VALLABH, SONIA MINIKEL | reporter.nih.gov |
| PERU Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,506,525 | December 1, 2024 | November 30, 2027 | SANCHEZ, JORGE LUIS | reporter.nih.gov |
| University of Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,173,751 | December 11, 2019 | November 30, 2026 | WALD, ANNA | reporter.nih.gov |
| A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $15,144,108 | September 15, 2021 | August 31, 2027 | CLARDY, STACEY LYNN | reporter.nih.gov |
| PHRU-Setshaba Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,110,381 | December 1, 2024 | November 30, 2027 | GRAY, GLENDA E | reporter.nih.gov |
| Consolidated Basic Cancer Research Program | NIH | National Cancer Institute | 2021 to 2025 | $14,936,465 | April 1, 1997 | February 28, 2026 | ALTIERI, DARIO C | reporter.nih.gov |
| Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,843,451 | August 20, 2021 | May 31, 2028 | NAJI, ALI | reporter.nih.gov |
| Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $14,399,999 | March 26, 2024 | February 28, 2029 | SAVIC, RADOJKA | reporter.nih.gov |
| University of Rochester Vaccine and Treatment Evaluation Unit (VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,263,529 | December 11, 2019 | November 30, 2026 | FALSEY, ANN R | reporter.nih.gov |
| Kaiser Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,173,633 | December 11, 2019 | November 30, 2026 | JACKSON, LISA A | reporter.nih.gov |
| Children's Oncology Group Pediatric Early Phase Clinical Trial Network | NIH | National Cancer Institute | 2021 to 2024 | $14,041,303 | May 3, 2024 | July 31, 2024 | WEIGEL, BRENDA J. | reporter.nih.gov |
| Admin. Supp.: Correction of Neurological Disease via Allele Specific Excision of Pathogenic Repeats | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $13,703,967 | May 15, 2023 | April 30, 2028 | DOUDNA, JENNIFER A | reporter.nih.gov |
| CURE SICKLE CELL INITIATIVE DATA STRATEGY AND DATA RESOURCES PROGRAM | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $13,440,748 | September 28, 2018 | December 31, 2026 | KRONER, BARBARA L | reporter.nih.gov |
| Protective immunity following dengue virus natural infections and vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,429,941 | July 29, 2015 | July 31, 2030 | HARRIS, EVA | reporter.nih.gov |
| Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,340,237 | April 10, 2020 | November 30, 2026 | MULLIGAN, MARK JOSEPH | reporter.nih.gov |
| Case Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,725,521 | December 1, 2024 | November 30, 2027 | YENDEWA, GEORGE | reporter.nih.gov |
| Respiratory pathogen-specific T cell signatures following vaccination, natural infection, and treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,580,221 | June 1, 2025 | May 31, 2027 | SETTE, ALESSANDRO | reporter.nih.gov |
| Development of an Antiviral to Combat Viral Infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $12,480,276 | November 15, 2022 | April 17, 2025 | CHANG, JINHONG | reporter.nih.gov |
| Georgetown University Lombardi Comprehensive Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $12,475,608 | July 1, 2025 | June 30, 2026 | WEINER, LOUIS M. | reporter.nih.gov |
| Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS (SEA-NOBI-ALS) | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $11,846,278 | September 1, 2024 | August 31, 2028 | OSKARSSON, BJORN E | reporter.nih.gov |
| (EET Biobank) NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank | NIH | National Cancer Institute | 2021 to 2025 | $11,843,510 | September 1, 2020 | March 31, 2027 | NICOL, KATHLEEN | reporter.nih.gov |
| Task A71: Comprehensive In Vivo Screening of Viral Pathogens of Pandemic Potential | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,745,278 | July 18, 2022 | July 17, 2025 | MORREY, JOHN | reporter.nih.gov |
| NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,660,249 | July 15, 2020 | October 31, 2025 | PHILLIPS, ELIZABETH | reporter.nih.gov |
| Development of an Optimized Adjuvanted TB Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,645,061 | September 30, 2021 | September 30, 2025 | EVANS, JAY | reporter.nih.gov |
| Cancer Center Support (CORE) Grant | NIH | National Cancer Institute | 2021 to 2025 | $11,628,123 | August 1, 1997 | June 30, 2030 | PALUCKA, ANNA KAROLINA | reporter.nih.gov |
| KwaZulu-Natal Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,302,268 | December 1, 2024 | November 30, 2027 | ABDOOL KARIM, QUARRAISHA | reporter.nih.gov |
| Pre-Symptomatic Familial ALS (Pre-fALS) Study: From Prodrome and Biomarkers to ALS/FTD Prevention | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $11,282,768 | September 15, 2018 | July 31, 2029 | BENATAR, MICHAEL | reporter.nih.gov |
| Center for Pre-Clinical Cancer Research | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $11,277,290 | March 1, 2021 | February 28, 2027 | FRANCIS, JOSEPH | reporter.nih.gov |
| Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,202,199 | March 15, 2007 | September 21, 2025 | SANNE, IAN MATTHIAS | reporter.nih.gov |
| Multi-Scale Investigations of Respiratory Mucus/Mucin Structure and Function in Health and Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $11,172,471 | August 15, 2022 | July 31, 2027 | BOUCHER, RICHARD CHARLES | reporter.nih.gov |
| Advancing Vaccine Adjuvant Research for Tuberculosis (TB) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $10,964,476 | September 30, 2022 | September 29, 2027 | BRITTON, WARWICK | reporter.nih.gov |
| Reagent Program for HIV and other Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,735,388 | October 15, 2023 | January 13, 2024 | RASHID, SUJATHA | reporter.nih.gov |
| Liver Cirrhosis Network: Scientific and Data Coordination Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $10,655,826 | August 28, 2021 | July 31, 2027 | SMITH, ABIGAIL | reporter.nih.gov |
| SPORE in Brain Cancer | NIH | National Cancer Institute | 2021 to 2025 | $10,413,880 | September 1, 2008 | August 31, 2029 | LANG, FREDERICK F | reporter.nih.gov |
| Colorado Head and Neck Cancer SPORE | NIH | National Cancer Institute | 2021 to 2025 | $10,073,085 | September 1, 2021 | August 31, 2026 | JIMENO, ANTONIO | reporter.nih.gov |
| Advanced Development of a Multivalent Vaccine Candidate for Lassa Fever | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,931,387 | September 1, 2017 | January 31, 2027 | SCHNELL, MATTHIAS JOHANNES | reporter.nih.gov |
| The Military HIV Research Program (MHRP) Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,676 | December 10, 2013 | November 30, 2027 | ROBB, MERLIN L | reporter.nih.gov |
| Silence ALS: A Platform for the Discovery and Development of Antisense Therapeutics for Patients with Ultra-Rare Forms of ALS | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $9,796,602 | March 1, 2024 | February 28, 2027 | SHNEIDER, NEIL ALAN | reporter.nih.gov |
| Thalamocortical Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $9,737,772 | June 1, 2021 | May 31, 2027 | MORRELL, MARTHA J | reporter.nih.gov |
| GHESKIO Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,655,243 | February 1, 2007 | November 30, 2027 | PAPE, JEAN WILLIAM | reporter.nih.gov |
| DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $9,566,206 | September 30, 2023 | September 29, 2026 | EVANS, JAY | reporter.nih.gov |
| Targeting the A2B Adenosine Receptor for Immunoprevention of Pancreatic Cancer | NIH | National Cancer Institute | 2021 to 2025 | $9,423,468 | September 15, 2023 | March 14, 2027 | WU, XIANGWEI | reporter.nih.gov |
| Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck Cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2024 | $9,412,704 | September 22, 2020 | June 30, 2026 | BURTNESS, BARBARA | reporter.nih.gov |
| 1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $9,400,136 | September 1, 2020 | June 25, 2024 | MARTINEZ, FERNANDO J | reporter.nih.gov |
| Development of a Novel Therapeutic for Melioidosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,235,577 | September 20, 2022 | September 30, 2026 | ALLEY, M.R.K. (DICKON) | reporter.nih.gov |
| Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $9,218,182 | August 24, 2022 | July 31, 2027 | BARKER, BRIDGET MARIE | reporter.nih.gov |
| Development of Therapeutic Candidates for Biodefense, Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $8,743,439 | September 25, 2023 | June 24, 2024 | RAMSTEDT, URBAN | reporter.nih.gov |
| FEND for TB supplement to accelerate BLINK X development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $8,340,332 | June 4, 2020 | May 31, 2025 | ELLNER, JERROLD J. | reporter.nih.gov |
| DartCF: The Dartmouth Cystic Fibrosis Research Center | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $7,832,026 | July 1, 2018 | August 31, 2030 | MADDEN, DEAN R | reporter.nih.gov |
| Seattle Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $7,698,581 | February 1, 2007 | November 30, 2027 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| FEND for TB | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,632,771 | June 4, 2020 | May 31, 2026 | ELLNER, JERROLD J. | reporter.nih.gov |
| Advanced Development of Vaccines for Filoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $7,417,867 | July 21, 2020 | December 31, 2026 | ELDRIDGE, JOHN | reporter.nih.gov |
| Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders | NIH | National Institute on Aging | 2021 to 2025 | $7,375,647 | July 1, 2021 | December 31, 2026 | REITZ, ALLEN BERNARD | reporter.nih.gov |
| "REAL Answers" (Registry Expansion Analyses to Learn) | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $7,362,213 | August 20, 2023 | July 31, 2028 | GLASSBERG, JEFFREY AVINS | reporter.nih.gov |
| TRANSPIRE: A Prospective Cohort Study of Lung Injury After Hematopoietic Stem Cell Transplant in Children. | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $7,251,380 | September 1, 2021 | May 31, 2027 | DAVIES, STELLA MARGARET | reporter.nih.gov |
| Coordinating center for the NCI small cell lung cancer research consortium | NIH | National Cancer Institute | 2021 to 2025 | $7,127,674 | June 24, 2022 | May 31, 2027 | RUDIN, CHARLES M. | reporter.nih.gov |
| Northwestern Cancer Prevention Consortium | NIH | National Cancer Institute | 2021 to 2025 | $7,062,222 | September 3, 2019 | July 31, 2031 | KHAN, SEEMA AHSAN | reporter.nih.gov |
| Molecules and Pathways at the Coccidioides Host-Pathogen Interface | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $7,052,234 | January 1, 2022 | December 31, 2026 | SIL, ANITA | reporter.nih.gov |
| iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials Consortium | NIH | National Cancer Institute | 2021 to 2025 | $7,046,172 | August 15, 2019 | July 31, 2031 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| 1/2 Sickel Cell Disease Treatment with Arginine Therapy (STArT Trial) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,920,555 | September 20, 2020 | August 31, 2026 | MORRIS, CLAUDIA R | reporter.nih.gov |
| Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,892,629 | September 15, 2004 | August 31, 2025 | FARRIS, A DARISE | reporter.nih.gov |
| Personalized prime editing as a platform for hepatic inborn errors of metabolism | NIH | National Center for Advancing Translational Sciences | 2024 to 2025 | $6,886,793 | September 20, 2024 | August 31, 2028 | AHRENS-NICKLAS, REBECCA CLARE | reporter.nih.gov |
| Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $6,819,944 | September 15, 2019 | August 31, 2025 | HORNIK, CHRISTOPH | reporter.nih.gov |
| Comparison of Symptom Burden/Toxicity, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients Treated with Proton vs. Photon Radiotherapy. | NIH | National Cancer Institute | 2021 to 2025 | $6,769,276 | March 1, 2021 | August 31, 2027 | KAHALLEY, LISA SCHUM | reporter.nih.gov |
| Subcutaneous Drug Development for Portal Hypertension Ascites | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $6,758,500 | September 22, 2014 | July 31, 2027 | CASTILLO, GERARDO M. | reporter.nih.gov |
| Aurum Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,678,965 | December 1, 2020 | November 30, 2027 | CHURCHYARD, GAVIN JOHN | reporter.nih.gov |
| A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,678,063 | May 1, 2019 | April 30, 2025 | RADOLF, JUSTIN D | reporter.nih.gov |
| Clinical Research in ALS and Related Disorders for Therapeutic Development (CReATe) | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $6,609,782 | September 30, 2014 | August 31, 2030 | BENATAR, MICHAEL | reporter.nih.gov |
| Facility and Building System Upgrades Support for the Howard T. Ricketts Biocontainment Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $6,593,067 | September 16, 2021 | February 28, 2025 | ADAMS, ERIN JUNE | reporter.nih.gov |
| Precision Editing of Granulin Mutations that Cause Frontotemporal Dementia | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $6,580,415 | August 15, 2025 | July 31, 2029 | SONTHEIMER, ERIK J. | reporter.nih.gov |
| Washington University/Siteman Cancer Center Lead Academic Site | NIH | National Cancer Institute | 2021 to 2025 | $6,572,668 | March 5, 2019 | February 28, 2026 | BARTLETT, NANCY L | reporter.nih.gov |
| Translational medicine and mechanistic studies of brain neurophysiology in Fragile X Syndrome | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $6,538,717 | September 25, 2020 | June 30, 2025 | ERICKSON, CRAIG | reporter.nih.gov |
| Stellenbosch University Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,524,563 | April 15, 2007 | November 30, 2027 | HESSELING, ANNEKE CATHARINA | reporter.nih.gov |
| Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,498,374 | August 1, 2017 | July 31, 2027 | WARE, RUSSELL E | reporter.nih.gov |
| Novel therapy for alcoholic liver disease-associated hepatorenal syndrome | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $6,485,223 | September 25, 2021 | August 31, 2027 | SUBRAMANIAN, MANI | reporter.nih.gov |
| METABOLIC ALDEHYDES AS IMMUNE EFFECTORS AGAINST TUBERCULOSIS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,434,161 | September 11, 2025 | August 31, 2029 | DARWIN, KATERINA HERAN | reporter.nih.gov |
| University of Washington (UW) Sexually Transmitted Infections (STI) Cooperative Research Center (CRC) - Syphilis Vaccine to Protect against Local and Disseminated T. pallidum Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,406,743 | August 1, 2019 | July 31, 2025 | WALD, ANNA | reporter.nih.gov |
| Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,398,428 | July 1, 2021 | June 30, 2027 | GENGENBACHER, MARTIN ALFONS | reporter.nih.gov |
| CAUSAL: Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan | NIH | National Cancer Institute | 2023 to 2025 | $6,381,605 | September 22, 2021 | August 31, 2027 | FRIEDMAN, DEBRA L. | reporter.nih.gov |
| Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL). | NIH | National Cancer Institute | 2021 to 2025 | $6,371,380 | September 1, 2021 | June 30, 2027 | BROOKS, DAVID G | reporter.nih.gov |
| Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain | NIH | National Center for Complementary & Integrative Health | 2021 to 2024 | $6,352,490 | September 21, 2020 | August 31, 2025 | DOORENBOS, ARDITH Z | reporter.nih.gov |
| Biologically informed design of CD8+ T cell-dependent pre-erythrocytic stage malaria vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,330,175 | February 4, 2021 | January 31, 2026 | KAPPE, STEFAN HI | reporter.nih.gov |
| Enhancing immunity to malaria in young children with effective chemoprevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,263,495 | July 1, 2025 | June 30, 2027 | JAGANNATHAN, PRASANNA | reporter.nih.gov |
| Translating genomic discoveries to improved outcomes for high risk acute leukemia | NIH | National Cancer Institute | 2021 to 2025 | $6,239,168 | January 19, 2017 | August 31, 2030 | MULLIGHAN, CHARLES G | reporter.nih.gov |
| BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIA | NIH | National Cancer Institute | 2022 to 2024 | $6,227,249 | June 15, 2022 | May 15, 2025 | CLAPPER, MARGIE L. | reporter.nih.gov |
| S4 TO 108 NCATS GENE THERAPY VECTOR | NIH | Office of the Director, National Institutes of Health | 2021 to 2023 | $6,133,050 | September 30, 2021 | September 29, 2024 | KOROLEVA, ANNA | reporter.nih.gov |
| Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,050,572 | September 20, 2019 | March 31, 2027 | SPINO, CATHERINE A | reporter.nih.gov |
| Metabolic gatekeepers in B-cell malignancies | NIH | National Cancer Institute | 2021 to 2025 | $5,936,594 | April 1, 2016 | August 31, 2028 | MÜSCHEN, MARKUS | reporter.nih.gov |
| Expanding the breadth, magnitude, and durability of PfSPZ vaccines by creating multi-strain vaccines, designer hybrid and genetically altered parasite vaccines and use of a unique adjuvant. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,933,702 | April 8, 2021 | March 31, 2027 | SIM, B. KIM LEE | reporter.nih.gov |
| Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $5,884,638 | August 1, 2020 | August 31, 2025 | CRYSTAL, RONALD G | reporter.nih.gov |
| Novel Biologic Therapies for GVHD | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $5,851,412 | February 1, 2010 | June 30, 2026 | KEAN, LESLIE S | reporter.nih.gov |
| SWITCH Trial: Early Feasibility Study of Stentrode BCI for Augmentative Communication | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $5,728,624 | August 15, 2021 | July 31, 2027 | WEBER, DOUGLAS J | reporter.nih.gov |
| 1/1: ARREST RESPIRATORY FAILURE DUE TO PNEUMONIA (ARREST PNEUMONIA) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $5,715,477 | September 23, 2019 | August 31, 2025 | LEVITT, JOSEPH ERIC | reporter.nih.gov |
| Pediatric Solid Tumor Microenvironment Atlas | NIH | National Cancer Institute | 2024 to 2025 | $5,678,350 | September 1, 2024 | August 31, 2029 | ASGHARZADEH, SHAHAB | reporter.nih.gov |
| Improving Neonatal health Through Rapid malaria testing in Early Pregnancy with high-sensitivity Diagnostics (INTREPiD) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,664,388 | April 1, 2022 | March 31, 2027 | TAYLOR, STEVE MYER | reporter.nih.gov |
| The role of stem cells and the microenvironment in gastrointestinal cancers | NIH | National Cancer Institute | 2021 to 2025 | $5,569,272 | January 7, 2016 | August 31, 2030 | WANG, TIMOTHY CRAGIN | reporter.nih.gov |
| DON in Pediatric Cerebral Malaria: A Phase I / II Dose-Escalation Safety Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,567,850 | June 1, 2025 | May 31, 2027 | POSTELS, DOUGLAS | reporter.nih.gov |
| Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,559,114 | June 17, 2020 | January 31, 2027 | WALZL, GERHARD | reporter.nih.gov |
| NHLBI MAINTENANCE OF CANINE MODELS OF HUMAN BLEEDING DISORDERS | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $5,542,798 | September 20, 2019 | September 19, 2024 | NICHOLS, TIMOTHY | reporter.nih.gov |
| Phase II clinical trial of transcranial direct current stimulation in the treatment of primary progressive aphasia | NIH | National Institute on Aging | 2022 to 2025 | $5,516,416 | September 30, 2022 | May 31, 2027 | HAMILTON, ROY H | reporter.nih.gov |
| DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,484,466 | August 21, 2020 | May 31, 2026 | NAHID, PAYAM | reporter.nih.gov |
| IND-Enabling Studies for Arenavirus Preclinical Candidate | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,459,651 | May 13, 2021 | January 31, 2027 | SOKOLOVA, NADEZDA V | reporter.nih.gov |
| Translational Control in Memory and Brain Disorders | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $5,426,946 | May 1, 2021 | April 30, 2029 | KLANN, ERIC | reporter.nih.gov |
| Developing computational models to predict the immune response to B. pertussis booster vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,401,756 | March 10, 2020 | February 28, 2025 | PETERS, BJOERN | reporter.nih.gov |
| Investigating the Benefits of Remotely-supervised Neuromodulation in Primary Progressive Aphasia | NIH | National Institute on Aging | 2025 | $5,343,452 | September 15, 2025 | August 31, 2029 | HENRY, MAYA | reporter.nih.gov |
| Chicago Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,330,849 | February 1, 2007 | November 30, 2027 | ACHENBACH, CHAD J | reporter.nih.gov |
| Translating Pathomechanisms into Treatment for Spinal Muscular Atrophies | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $5,290,574 | May 5, 2021 | April 30, 2029 | SUMNER, CHARLOTTE JANE | reporter.nih.gov |
| A Human iPSC-based Cell Therapy for Canavan Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $5,276,950 | June 15, 2021 | May 31, 2027 | SHI, YANHONG | reporter.nih.gov |
| New Mechanistic Insights & Therapeutic Applications of Megakaryocytes/Platelets | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $5,258,818 | May 1, 2020 | April 30, 2027 | PONCZ, MORTIMER | reporter.nih.gov |
| Lung Adenocarcinoma: From Genome Alterations to Therapeutic Discovery | NIH | National Cancer Institute | 2021 to 2025 | $5,246,301 | August 1, 2015 | July 31, 2028 | MEYERSON, MATTHEW L. | reporter.nih.gov |
| System Wide Operations for Rare Disorders (SWORD) | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $5,227,397 | September 30, 2009 | June 30, 2025 | KIM, HELEN | reporter.nih.gov |
| Advancing RNA Therapeutics for Huntington’s Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $5,226,511 | February 1, 2020 | January 31, 2026 | ARONIN, NEIL | reporter.nih.gov |
| Novel therapeutic development for small cell lung cancer | NIH | National Cancer Institute | 2021 to 2025 | $5,214,420 | August 10, 2021 | July 31, 2028 | RUDIN, CHARLES M. | reporter.nih.gov |
| Advancement of a poxvirus antiviral | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,192,454 | March 12, 2020 | August 31, 2029 | CONNOR, JOHN H | reporter.nih.gov |
| Digital Health Technologies for Monitoring Motor Function in Progressive Supranuclear Palsy and Dementia with Lewy Bodies | NIH | National Institute on Aging | 2025 | $5,174,076 | September 1, 2025 | August 31, 2029 | VAZIRI, ASHKAN | reporter.nih.gov |
| Reading mitochondrial apoptotic signaling to identify active cancer therapeutics | NIH | National Cancer Institute | 2021 to 2025 | $5,159,959 | August 1, 2019 | September 29, 2025 | LETAI, ANTHONY G | reporter.nih.gov |
| Fecal Microbiota Transplantation and Fiber for the Treatment of Graft-versus-host Disease After Hematopoietic Cell Transplantation | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $5,128,451 | September 1, 2023 | June 30, 2027 | FREDRICKS, DAVID NEAL | reporter.nih.gov |
| Targeting Dysregulated RNA Splicing in Neurodegenerative Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $5,093,143 | September 1, 2023 | August 31, 2028 | LAGIER-TOURENNE, CLOTILDE | reporter.nih.gov |
| Focal mass drug administration (fMDA) to reduce Plasmodium vivax transmission, a pragmatic cluster randomized controlled trial in Peru | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $5,036,878 | June 1, 2025 | May 31, 2027 | HSIANG, MICHELLE SANG | reporter.nih.gov |
| Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2024 | $5,036,160 | September 1, 2022 | August 31, 2027 | CHANG, AILEEN | reporter.nih.gov |
| Identifying the mechanisms of leukemia progression | NIH | National Cancer Institute | 2021 to 2025 | $5,032,279 | September 22, 2021 | August 31, 2028 | CRISPINO, JOHN D | reporter.nih.gov |
| DEVELOPMENT OF PAN-FILOVIRUS THERAPEUTICS | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $5,008,204 | November 1, 2022 | March 1, 2027 | BOWLIN, TERRY | reporter.nih.gov |
| Developing a kit-based research use only (RUO) translocation assay for deployment as a lab developed test (LDT) toward changing outcomes for patients with driver-negative tumors | NIH | National Cancer Institute | 2021 to 2024 | $4,982,588 | May 1, 2020 | April 30, 2025 | SELVARAJ, SIDDARTH | reporter.nih.gov |
| Leveraging Natural Phenotypic Variations of Heterogenous ALS Populations-in-a-Dish to Enable Scalable Drug Discovery | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $4,949,698 | September 18, 2022 | August 31, 2027 | ICHIDA, JUSTIN KAWIKA | reporter.nih.gov |
| Bacteriophage-based approach for managing Shigella infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,946,719 | May 5, 2020 | April 30, 2026 | SULAKVELIDZE, ALEXANDER | reporter.nih.gov |
| Targeting the MYC Pathway for the Treatment of Cancer | NIH | National Cancer Institute | 2021 to 2025 | $4,931,456 | September 8, 2020 | August 31, 2027 | FELSHER, DEAN W | reporter.nih.gov |
| Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2024 | $4,927,507 | May 5, 2010 | August 31, 2025 | VANDENBORNE, KRISTA H | reporter.nih.gov |
| Preclinical development of a vaccine for Nipah virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,912,518 | March 11, 2021 | February 28, 2027 | GEISBERT, THOMAS WILLIAM | reporter.nih.gov |
| Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $4,889,710 | June 7, 2024 | June 1, 2026 | BRUYETTE, DAVID | reporter.nih.gov |
| Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $4,856,116 | September 15, 2021 | August 31, 2026 | SEPULVEDA, PATRICIO | reporter.nih.gov |
| Accelerating discovery of an efficacious Plasmodium vivax multivalent multi-stage vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,835,728 | December 1, 2020 | November 30, 2026 | ADAMS, JOHN H | reporter.nih.gov |
| From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $4,812,450 | September 12, 2023 | July 31, 2030 | DALLA-FAVERA, RICCARDO | reporter.nih.gov |
| Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,809,096 | April 15, 2020 | March 31, 2026 | DORSEY, MATTHEW G | reporter.nih.gov |
| Novel Stem Cell Immunotherapy for MDR-Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,800,190 | June 4, 2021 | May 31, 2026 | JAGANNATH, CHINNASWAMY | reporter.nih.gov |
| Genomic medicine and gene function implementation for an underserved population | NIH | National Human Genome Research Institute | 2021 to 2025 | $4,796,292 | July 13, 2021 | April 30, 2027 | BELLEN, HUGO J | reporter.nih.gov |
| A Phase I Clinical Trial Testing Feasibility of Hematopoietic Stem Cell Gene Therapy Using Platelet Factor VIII to Safely Improve Hemostasis for Severe Hemophilia A with Inhibitory Antibodies | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $4,780,411 | April 5, 2019 | March 31, 2026 | WILCOX, DAVID ALLEN | reporter.nih.gov |
| Mechanistic studies of chromatin modification in transcription regulation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,727,113 | February 14, 2019 | April 30, 2029 | WOLBERGER, CYNTHIA | reporter.nih.gov |
| Investigating molecular and cellular mechanisms of SCLC development to identify novel therapeutic strategies | NIH | National Cancer Institute | 2021 to 2025 | $4,726,654 | September 9, 2019 | August 31, 2026 | SAGE, JULIEN | reporter.nih.gov |
| Metabolic Influences on Complex Tumor Neighborhoods | NIH | National Cancer Institute | 2021 to 2025 | $4,722,150 | August 1, 2017 | July 31, 2030 | SIMON, M. CELESTE | reporter.nih.gov |
| Development of Non-Human Primate Models to Assess Immunological Mechanisms and Antigenic Targets of Protective Sporozoite (SPZ) Vaccines and Establish Superior Efficacy of Next Generation SPZ vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,717,265 | April 1, 2021 | March 31, 2027 | HOFFMAN, STEPHEN LEV | reporter.nih.gov |
| PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,716,636 | May 1, 2025 | April 30, 2027 | KOENIG, SERENA PATRICIA | reporter.nih.gov |
| DEVELOPMENT OF SAPONIN DMLT ADJUVANT (SDA) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,695,387 | September 30, 2023 | September 29, 2026 | NORTON, ELIZABETH | reporter.nih.gov |
| Multi-site validation of biomarkers and core clinical outcome measures for clinical trial readiness in CDKL5 Deficiency Disorder - Supplement | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $4,693,682 | February 15, 2021 | January 31, 2027 | BENKE, TIMOTHY A | reporter.nih.gov |
| Mechanisms of innate immune dysfunction in SIV/malaria co-infection in pregnancy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $4,672,308 | September 24, 2021 | July 31, 2026 | MANUZAK, JENNIFER | reporter.nih.gov |
| Development of Innovative Resources to Advance MDS Research | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $4,661,966 | September 15, 2023 | July 31, 2028 | BLEAKLEY, MARIE | reporter.nih.gov |
| Clinical Trial Site Monitoring for PHOENIx MDR-TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,653,435 | April 15, 2025 | December 14, 2025 | SMITH, KIMBERLY | reporter.nih.gov |
| DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,647,135 | June 29, 2020 | May 31, 2026 | ANTIA, RUSTOM NOSHIR | reporter.nih.gov |
| Nephrotic Syndrome Rare Disease Clinical Research Network III | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $4,641,008 | September 8, 2009 | June 30, 2025 | KRETZLER, MATTHIAS | reporter.nih.gov |
| MYCOBACTERIUM TUBERCULOSIS (MTB) QUALITY ASSESSMENT PROGRAM (TBQA) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,608,548 | January 1, 2023 | December 31, 2023 | COFFIN, JEANETTE | reporter.nih.gov |
| Proteogenomic characterization of early and late resistance mechanisms in acute myeloid leukemia | NIH | National Cancer Institute | 2022 to 2025 | $4,603,890 | June 15, 2022 | May 31, 2027 | TYNER, JEFFREY WALLACE | reporter.nih.gov |
| A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform | NIH | National Center for Advancing Translational Sciences | 2021 to 2024 | $4,598,428 | July 1, 2021 | April 30, 2026 | HINGTGEN, SHAWN | reporter.nih.gov |
| Chemical Approaches to Modulate PAX3-FOXO1 in Fusion-Positive Alveolar Rhabdomyosarcoma | NIH | National Cancer Institute | 2024 to 2025 | $4,597,865 | September 6, 2024 | August 31, 2029 | KOEHLER, ANGELA NICOLE | reporter.nih.gov |
| Molecular and Cellular Regulation of Pre-Leukemic Stem Cells and their Therapeutic Targeting | NIH | National Cancer Institute | 2021 to 2025 | $4,594,192 | September 1, 2021 | August 31, 2028 | STEIDL, ULRICH | reporter.nih.gov |
| Targeting transcriptional addiction in fusion-driven sarcoma | NIH | National Cancer Institute | 2024 to 2025 | $4,553,009 | July 8, 2024 | June 30, 2029 | MCFADDEN, DAVID GLENN | reporter.nih.gov |
| Therapeutic Targeting of Human AML Stem Cells | NIH | National Cancer Institute | 2021 to 2025 | $4,546,001 | September 8, 2020 | August 31, 2027 | JORDAN, CRAIG T. | reporter.nih.gov |
| A systems analysis of drug tolerance in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,414,678 | December 1, 2016 | June 30, 2027 | BALIGA, NITIN S | reporter.nih.gov |
| Vaccine and Treatment Evaluation Units: Wolbachia-Infected Aedes aegypti Mosquitos in Reducing Arboviral Infection Brazil | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,402,306 | February 4, 2020 | November 30, 2027 | ROUPHAEL, NADINE | reporter.nih.gov |
| Pediatric Early Phase Clinical Trials Network (PEP-CTN) Transfer Application | NIH | National Cancer Institute | 2025 | $4,394,441 | August 1, 2025 | July 31, 2029 | FOX, ELIZABETH | reporter.nih.gov |
| ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC) | NIH | National Cancer Institute | 2021 to 2025 | $4,374,283 | March 1, 2025 | February 28, 2026 | LEVINE, ROSS L | reporter.nih.gov |
| Genetic Susceptibility and Biomarkers of Platinum-related Toxicities | NIH | National Cancer Institute | 2021 to 2025 | $4,370,186 | September 25, 2012 | June 30, 2027 | TRAVIS, LOIS B. | reporter.nih.gov |
| Innovating Yeast and Human Genetics Approaches to Define Mechanisms of Neurodegenerative Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $4,359,590 | December 1, 2016 | November 30, 2024 | GITLER, AARON D. | reporter.nih.gov |
| Alleviation of ER stress as a translational strategy to curb ocular viral infections | NIH | National Eye Institute | 2022 to 2025 | $4,325,995 | March 1, 2022 | December 31, 2026 | SHUKLA, DEEPAK | reporter.nih.gov |
| Pediatric Oncology In Vivo Testing Program Coordinating Center | NIH | National Cancer Institute | 2021 to 2025 | $4,288,627 | August 25, 2021 | June 30, 2026 | BULT, CAROL J | reporter.nih.gov |
| KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,284,115 | March 22, 2021 | February 28, 2027 | OGEMBO, JAVIER GORDON | reporter.nih.gov |
| Porphyrias Consortium | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $4,280,404 | September 30, 2009 | June 30, 2025 | DESNICK, ROBERT J | reporter.nih.gov |
| The Role of the MBD2-NuRD Complex in Gamma-Globin Gene Silencing | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $4,278,408 | August 1, 2018 | August 31, 2029 | GINDER, GORDON D | reporter.nih.gov |
| Mayo Clinic Center for Clinical Proteomics | NIH | National Cancer Institute | 2022 to 2025 | $4,271,766 | June 1, 2022 | May 31, 2027 | PANDEY, AKHILESH | reporter.nih.gov |
| Aerosolized Vitamin A: Developing a Prevention for Hyperoxic Lung Injury and Bronchopulmonary Dysplasia, with Focus on Neonatal Lung Maturation | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,252,869 | July 1, 2018 | February 28, 2027 | GELFAND, CRAIG | reporter.nih.gov |
| A selective angiogenesis blocker to treat retinopathy of prematurity | NIH | National Eye Institute | 2021 to 2023 | $4,248,825 | February 1, 2019 | December 31, 2025 | LI, WEI | reporter.nih.gov |
| Preventing TB with intravenous BCG in SIV-infected macaques | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,248,442 | May 5, 2021 | April 30, 2026 | SCANGA, CHARLES A. | reporter.nih.gov |
| Dystonia Coalition | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2023 | $4,243,735 | September 30, 2009 | August 31, 2025 | JINNAH, HYDER A | reporter.nih.gov |
| Comprehensive Characterization of the T-cell Response to KSHV to Enable Specific Immune Therapy | NIH | National Cancer Institute | 2025 | $4,234,248 | September 19, 2025 | August 31, 2029 | WARREN, EDUS HOUSTON | reporter.nih.gov |
| Molecular Regulation of Progressive Pulmonary Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,220,741 | March 1, 2020 | February 28, 2027 | NOBLE, PAUL WESLEY | reporter.nih.gov |
| The Long-Acting/Extended Release Antiretroviral Resource Program (LEAP) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,204,220 | May 15, 2015 | June 30, 2030 | FLEXNER, CHARLES W. | reporter.nih.gov |
| Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2024 | $4,182,561 | May 1, 2024 | August 31, 2025 | ESBENSEN, ANNA J. | reporter.nih.gov |
| Metabolic reprogramming of the tumor microenvironment and therapy resistance | NIH | National Cancer Institute | 2021 to 2025 | $4,171,362 | August 17, 2021 | July 31, 2028 | LENGYEL, ERNST | reporter.nih.gov |
| Structural Analysis and Inhibitor Optimization of Cryptosporidium n-myristoyltransferase for Drug Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,163,372 | November 15, 2020 | October 31, 2026 | STAKER, BART LEE | reporter.nih.gov |
| Role of Inducible Bronchus Associated Lymphoid Tissue in Latent Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,152,012 | February 1, 2023 | January 31, 2027 | KHADER, SHABAANA A. | reporter.nih.gov |
| Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $4,136,457 | September 20, 2021 | June 30, 2027 | CHELSKY, DANIEL | reporter.nih.gov |
| Development of mRNA-platform vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,121,318 | January 21, 2021 | December 31, 2026 | DAMRON, FREDRICK HEATH | reporter.nih.gov |
| Integrating human and non-human primate data to understand the acquisition of pre-erythrocytic immunity in the face of previous malaria exposure | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,114,200 | February 10, 2022 | January 31, 2027 | WILDER, BRANDON KEITH | reporter.nih.gov |
| New chemotherapy regimens and biomarkers for Chagas disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,104,835 | August 17, 2018 | July 31, 2025 | ALMEIDA, IGOR C | reporter.nih.gov |
| Development of an oral liver-targeted prime-and-trap malaria vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,104,491 | December 1, 2020 | November 30, 2026 | MURPHY, SEAN C | reporter.nih.gov |
| Optimization of an in vivo base editing strategy to treat SOD1-linked ALS | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $4,091,010 | July 25, 2025 | November 30, 2026 | GAJ, THOMAS | reporter.nih.gov |
| A STINGing vaccine for TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,090,805 | June 1, 2020 | May 31, 2026 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Parasitic Ulcer Treatment Trial | NIH | National Eye Institute | 2023 to 2025 | $4,068,111 | September 30, 2023 | March 31, 2028 | KEENAN, JEREMY DAVID | reporter.nih.gov |
| Optimization of Lead BKIs for Cryptosporidiosis Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,065,300 | January 1, 2021 | December 31, 2026 | VAN VOORHIS, WESLEY C | reporter.nih.gov |
| Clinical and genetic risk factors associated with adverse long-term health outcomes after curative therapies in individuals with sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,065,243 | March 15, 2021 | February 28, 2027 | DEBAUN, MICHAEL R. | reporter.nih.gov |
| Manganese Based MRI Contrast Agent | NIH | National Cancer Institute | 2023 to 2024 | $4,050,000 | June 5, 2023 | May 31, 2026 | HOFFMAN, VERA | reporter.nih.gov |
| Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $4,042,959 | January 25, 2023 | December 31, 2027 | LOUIE, ARNOLD | reporter.nih.gov |
| Stalled replication fork repair in cancer predisposition and cancertherapy | NIH | National Cancer Institute | 2022 to 2025 | $4,040,847 | August 10, 2022 | July 31, 2029 | SCULLY, RALPH | reporter.nih.gov |
| A personalized approach using hypoxia resolution to guide curative-intent radiation dose reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers | NIH | National Cancer Institute | 2021 to 2025 | $4,028,888 | March 3, 2020 | March 31, 2030 | LEE, NANCY Y | reporter.nih.gov |
| Defining functional humoral correlates of immunity to guide vaccine design | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,023,233 | November 24, 2020 | October 31, 2025 | BATISTA, FACUNDO DAMIAN | reporter.nih.gov |
| Base editing and prime editing for sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,000,055 | January 1, 2021 | June 30, 2030 | WEISS, MITCHELL J | reporter.nih.gov |
| Implantable iontophoresis chemotherapy delivery device for direct infusion ofgemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial | NIH | National Cancer Institute | 2021 to 2022 | $4,000,000 | September 17, 2017 | July 31, 2024 | DAUNCH, WILLIAM ANDREW | reporter.nih.gov |
| Development of GPER Agonists as Therapeuticsfor Cutaneous and Uveal Melanoma | NIH | National Cancer Institute | 2022 to 2023 | $4,000,000 | March 16, 2018 | March 31, 2024 | GARYANTES, TINA | reporter.nih.gov |
| Phase 1b/2a Trial of QBS-72S for the Treatment of Newly Diagnosed Glioblastoma Multiforme in Patients with Unmethylated MGMT Promoters | NIH | National Cancer Institute | 2021 to 2025 | $3,999,763 | June 1, 2013 | August 31, 2026 | RINGOLD, GORDON M | reporter.nih.gov |
| Commercializing CivaSheet for Pancreatic Cancer Patients | NIH | National Cancer Institute | 2023 to 2025 | $3,999,206 | September 13, 2016 | June 30, 2026 | PEREZ, KRISTY | reporter.nih.gov |
| Development of a protein drug for pancreatic cancer treatment | NIH | National Cancer Institute | 2022 to 2024 | $3,994,217 | September 26, 2017 | January 31, 2025 | LIU, ZHI-REN | reporter.nih.gov |
| Combining Targeted RIT and Synergistic Novel Agent-Renewal | NIH | National Cancer Institute | 2021 to 2025 | $3,984,924 | June 1, 2020 | May 31, 2027 | OROZCO, JOHNNIE JOSE | reporter.nih.gov |
| Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | NIH | National Cancer Institute | 2021 to 2025 | $3,984,664 | July 16, 2018 | January 31, 2027 | BICKEL, KELLIE | reporter.nih.gov |
| Training Program in Nervous System Tumors | NIH | National Cancer Institute | 2021 to 2025 | $3,975,290 | September 26, 2001 | August 31, 2027 | PLOTKIN, SCOTT R | reporter.nih.gov |
| BIOREPOSITORY OF HUMAN INDUCED PLURIPOTENT STEM CELLSFORCARDIOVASCULAR DISEASES (BHIPSC-CVD)- TASK A. CORE STUDY OPERATIONS | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,969,819 | September 1, 2020 | August 31, 2025 | WU, JOSEPH | reporter.nih.gov |
| IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,969,244 | March 7, 2019 | March 31, 2026 | AUCI, DOMINICK | reporter.nih.gov |
| NextGen - CRI | NIH | National Cancer Institute | 2022 to 2025 | $3,968,330 | June 1, 2025 | May 31, 2026 | BOLLARD, CATHERINE M. | reporter.nih.gov |
| Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,954,829 | April 15, 2011 | June 30, 2027 | ICHTCHENKO, KONSTANTIN | reporter.nih.gov |
| Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $3,953,139 | March 8, 2024 | February 28, 2026 | EKINS, SEAN | reporter.nih.gov |
| Preclinical development of breakthrough immunotherapy for brain tumors | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,949,492 | December 15, 2017 | November 30, 2025 | OKADA, HIDEHO | reporter.nih.gov |
| The power of extracellular vesicles in glioblastoma | NIH | National Cancer Institute | 2021 to 2024 | $3,947,064 | September 6, 2018 | August 31, 2025 | BREAKEFIELD, XANDRA OWENS | reporter.nih.gov |
| Optimizing Ridaifen-B analogs as potential therapeutics for Ebola viruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,937,392 | September 20, 2022 | July 31, 2027 | RONG, LIJUN | reporter.nih.gov |
| Discovering mechanisms of neuroblastoma tumorigenesis to improve patient outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,932,444 | September 30, 2017 | August 31, 2032 | MARIS, JOHN M | reporter.nih.gov |
| The role of clonal hematopoiesis in the development and therapy of myeloid malignancies | NIH | National Cancer Institute | 2021 to 2024 | $3,926,618 | August 15, 2020 | November 1, 2024 | EBERT, BENJAMIN LEVINE | reporter.nih.gov |
| Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,925,773 | July 1, 2021 | April 30, 2027 | DUNCAN, JOSEPH A | reporter.nih.gov |
| A systems immunology approach to evaluate malaria vaccine performance in endemic regions of Kenya | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,921,000 | February 1, 2022 | January 31, 2027 | MOORMANN, ANN M | reporter.nih.gov |
| Imaging and Molecular Phenotyping of Cystic Fibrosis Lung Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,919,631 | February 3, 2021 | January 31, 2027 | CLEVELAND, ZACKARY I | reporter.nih.gov |
| Frontotemporal dementia and related disorders: transcriptomic profiling, biomarker discovery, and mechanistic insight | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,904,675 | April 15, 2021 | March 31, 2027 | VAN BLITTERSWIJK, MARKA | reporter.nih.gov |
| CCL2 and CCR2 as metastatic drivers and therapeutic targets in medulloblastoma | NIH | National Cancer Institute | 2021 to 2025 | $3,903,008 | January 1, 2021 | December 31, 2025 | WEISS, WILLIAM A | reporter.nih.gov |
| Development of a novel TB vaccine safer and more effective than BCG based on a precisely controlled replication-limited Mycobacterium tuberculosis engineered for optimal in vivo growth and clearance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,876,556 | March 15, 2021 | February 28, 2027 | HORWITZ, MARCUS AARON | reporter.nih.gov |
| Development of small molecule inhibitors of metabolic enzymes as broad spectrum anthelmintic drugs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,860,924 | March 11, 2021 | February 28, 2027 | MITREVA, MAKEDONKA | reporter.nih.gov |
| Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,856,328 | September 1, 2019 | August 31, 2029 | LIN, GANG | reporter.nih.gov |
| Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation | NIH | National Cancer Institute | 2022 to 2025 | $3,855,091 | September 22, 2022 | August 31, 2027 | MARKOWITZ, SANFORD D. | reporter.nih.gov |
| Precision Medicine in the Acute Respiratory Distress Syndrome | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,851,458 | January 16, 2018 | March 31, 2025 | CALFEE, CAROLYN | reporter.nih.gov |
| Immunomodulation Approaches to Improve Safety And Efficacy of Gene Therapy Treatment in Friedreich’s Ataxia | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,844,243 | May 1, 2021 | August 31, 2026 | CORTI, MANUELA | reporter.nih.gov |
| Optimization of novel phenotypic screening hits for treatment of Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,843,960 | April 1, 2021 | March 31, 2027 | PHILLIPS, MARGARET A. | reporter.nih.gov |
| Mechanisms of protection against shigellosis in children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,843,317 | June 9, 2022 | May 31, 2027 | PASETTI, MARCELA F | reporter.nih.gov |
| Advancing an XIST ASO candidate for the treatment of Rett Syndrome | NIH | National Institute of Mental Health | 2021 to 2025 | $3,842,186 | July 1, 2019 | February 28, 2029 | LEE, JEANNIE T | reporter.nih.gov |
| Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level | NIH | National Cancer Institute | 2022 to 2025 | $3,840,901 | September 21, 2022 | August 31, 2027 | CALIFANO, ANDREA | reporter.nih.gov |
| In vivo Drug Testing of Pediatric CNS Tumors Using Patient Derived Orthotopic Xenograft Models | NIH | National Cancer Institute | 2021 to 2025 | $3,829,886 | July 14, 2015 | June 30, 2026 | LI, XIAONAN | reporter.nih.gov |
| Novel therapeutics for FSHD | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $3,829,831 | September 10, 2008 | May 31, 2024 | EMERSON, CHARLES P. | reporter.nih.gov |
| Identification of novel immunogenic proteins from Bordetella pertussis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,825,567 | June 9, 2021 | May 31, 2027 | DUBEY, PURNIMA | reporter.nih.gov |
| Systems Biology of Bone Marrow Failure and MDS for Precision Medicine | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2023 | $3,813,084 | September 15, 2019 | June 30, 2024 | SHIMAMURA, AKIKO | reporter.nih.gov |
| Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,809,183 | August 1, 2015 | July 31, 2030 | LARSEN, MICHELLE H | reporter.nih.gov |
| Models for Therapy of Hereditary Retinal Degeneration | NIH | National Eye Institute | 2021 to 2025 | $3,791,872 | December 1, 1992 | December 31, 2029 | BELTRAN, WILLIAM A. | reporter.nih.gov |
| Human natural killer cells: Advancing biology and clinical applications | NIH | National Cancer Institute | 2021 to 2025 | $3,769,374 | July 21, 2017 | June 30, 2032 | CALIGIURI, MICHAEL A | reporter.nih.gov |
| Enhance UCSC Xena: extend interactive visualization to ultra-large-scale multi-omics data and integrate with analysis resources | NIH | National Cancer Institute | 2021 to 2025 | $3,765,580 | September 1, 2021 | August 31, 2027 | ZHU, JINGCHUN | reporter.nih.gov |
| O-Specific Polysaccharide Responses and Cholera | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,758,033 | August 7, 2013 | March 31, 2030 | RYAN, EDWARD T. | reporter.nih.gov |
| Targeting the Genus Leishmania with Small Molecules | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,752,432 | March 24, 2021 | February 28, 2026 | SCHAUS, SCOTT EDWARD | reporter.nih.gov |
| Dissecting CCL5 contribution to antigen specific T cell responses in head and neck cancers | NIH | National Institute of Dental & Craniofacial Research | 2025 | $3,742,682 | August 21, 2025 | August 20, 2029 | UPPALURI, RAVINDRA | reporter.nih.gov |
| Molecular Imaging CCR2 Lung Inflammation and Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,741,003 | February 5, 2021 | December 31, 2026 | BRODY, STEVEN | reporter.nih.gov |
| Systematic Investigation of Protein Ubiquitination in ARDS | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,737,220 | January 26, 2018 | November 30, 2025 | CHEN, BEIBEI | reporter.nih.gov |
| Validating the Flavivirus Envelope Protein as an Antiviral Target | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,735,490 | March 1, 2020 | February 28, 2026 | YANG, PRISCILLA LI-NING | reporter.nih.gov |
| Studies on the structure of basement membranes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,732,265 | September 1, 1986 | June 30, 2029 | HUDSON, BILLY GERALD | reporter.nih.gov |
| Bacteria and Host in TB Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $3,731,271 | April 10, 2020 | March 31, 2023 | ALLAND, DAVID | reporter.nih.gov |
| Lead Optimization of DHODH Inhibitors for Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,721,559 | January 1, 2013 | June 30, 2028 | PHILLIPS, MARGARET A. | reporter.nih.gov |
| Discovery of Adjuvants that Direct T-cell Fates for Improved Safety and Efficacy in Vaccines Against Influenza and Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,714,524 | September 30, 2025 | September 29, 2026 | ESSER-KAHN, AARON | reporter.nih.gov |
| A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,713,909 | August 21, 2019 | July 31, 2025 | KIRKPATRICK, BETH DIANE | reporter.nih.gov |
| Structure-based design of broad flavivirus immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,710,975 | September 24, 2021 | August 31, 2026 | LAI, JONATHAN R. | reporter.nih.gov |
| Novel therapeutic gene editing to induce fetal hemoglobin for sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,710,340 | September 1, 2023 | August 31, 2028 | WEISS, MITCHELL J | reporter.nih.gov |
| Translational Gene Therapy for CNGB1 Retinitis Pigmentosa | NIH | National Eye Institute | 2021 to 2022 | $3,709,328 | April 1, 2018 | July 31, 2025 | PETERSEN-JONES, SIMON | reporter.nih.gov |
| Proteogenomic translator for cancer biomarker discovery towards precision medicine | NIH | National Cancer Institute | 2022 to 2025 | $3,707,896 | May 1, 2025 | April 30, 2026 | WANG, PEI | reporter.nih.gov |
| Genetic modifiers of Duchenne Muscular Dystrophy | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $3,704,232 | May 15, 2014 | July 31, 2027 | FLANIGAN, KEVIN M | reporter.nih.gov |
| Conduct Synthesis and Acquire Batches of Compounds for Subsequent Biological In Vitro and In Vivo Testing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,702,250 | April 1, 2024 | March 31, 2025 | MIDDLETON, MARK | reporter.nih.gov |
| Protein structural biophysics driving drug discovery for cardiac calcium transport regulation, producing translational advances and mechanistic insights | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,701,653 | May 1, 2020 | April 30, 2028 | THOMAS, DAVID D | reporter.nih.gov |
| Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological Malignancies | NIH | National Cancer Institute | 2021 to 2025 | $3,687,540 | September 7, 2017 | June 30, 2032 | DIPERSIO, JOHN F. | reporter.nih.gov |
| Evaluation of Antibody Responses Elicited by Zika Vaccination in Flavivirus-naïve and -experienced Individuals | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,665,742 | April 13, 2021 | March 31, 2027 | KREBS, SHELLY J | reporter.nih.gov |
| Minocycline as a potential therapy for neuroinflammation and cognitive deficit in sickle cell disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,659,814 | December 15, 2020 | November 30, 2026 | HYACINTH, HYACINTH IDU | reporter.nih.gov |
| Single-Cell Transcriptional and Epigenomic Dissection to Identify Therapeutic Targets for ALS and FTD | NIH | National Institute on Aging | 2021 to 2025 | $3,657,244 | March 1, 2021 | November 30, 2026 | KELLIS, MANOLIS | reporter.nih.gov |
| Characterization of brain dysfunction during development in survivors of childhood acute lymphoblastic leukemia | NIH | National Cancer Institute | 2021 to 2024 | $3,657,208 | March 1, 2020 | February 28, 2026 | SUSSMAN, ELYSE S | reporter.nih.gov |
| Michigan Center for Translational Cancer Proteogenomics | NIH | National Cancer Institute | 2022 to 2025 | $3,656,494 | June 6, 2022 | May 31, 2027 | NESVIZHSKII, ALEXEY I | reporter.nih.gov |
| The Bring BPaL2Me Trial - Comparing Nurse-Led RR-TB Treatment in Primary Care to Physician-Led, Hospital-Based RR-TB Treatment: A Cluster Randomized, Non-Inferiority Trial | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,655,506 | March 10, 2023 | February 29, 2028 | FARLEY, JASON EDWARD | reporter.nih.gov |
| Pediatric Preclinical In Vivo Testing Center for Pediatric Sarcoma and Other Solid Tumors | NIH | National Cancer Institute | 2021 to 2025 | $3,652,183 | July 1, 2021 | June 30, 2026 | KUNG, ANDREW L | reporter.nih.gov |
| Nuclear and Glial Dysfunction in Neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $3,647,532 | May 16, 2023 | April 30, 2031 | ROTHSTEIN, JEFFREY D | reporter.nih.gov |
| Fosinopril analogs for the treatment of human babesiosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,646,365 | April 21, 2021 | March 31, 2027 | BEN MAMOUN, CHOUKRI | reporter.nih.gov |
| Trial of Statins for Chemoprevention in Hepatocellular Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $3,646,155 | September 1, 2021 | August 31, 2027 | CHUNG, RAYMOND T | reporter.nih.gov |
| Clinical Trial Readiness for Multiple System Atrophy - Resubmission - 1 | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $3,632,800 | April 15, 2022 | March 31, 2028 | KAUFMANN, HORACIO | reporter.nih.gov |
| In Vivo Testing of Novel Drug Combinations for Pediatric Soft Tissue Sarcomas | NIH | National Cancer Institute | 2021 to 2025 | $3,632,740 | July 1, 2021 | June 30, 2027 | DYER, MICHAEL A | reporter.nih.gov |
| NGTC - UCL | NIH | National Cancer Institute | 2022 to 2024 | $3,627,871 | June 1, 2024 | May 31, 2025 | PULE, MARTIN | reporter.nih.gov |
| IND Enabling Studies and Manufacturing Scale Up of Human Placental Extract to Prevent Surgical Necrotizing Enterocolitis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,623,857 | July 2, 2020 | May 31, 2027 | BERGER, MICHAEL BENTLEY | reporter.nih.gov |
| Synthetic Nanoparticle-antibody (SNAb) Based Depletion of Myeloid-Derived Suppressor Cells for TB Host-Directed Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,610,454 | August 5, 2021 | July 31, 2025 | RENGARAJAN, JYOTHI | reporter.nih.gov |
| Polyalanine Tails: A Novel Type of Protein Modification Implicated in Neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,598,452 | August 1, 2017 | May 31, 2027 | BURGESS, ROBERT W. | reporter.nih.gov |
| Development of a Replicon RNA-based Vaccine against Dengue and Zika | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,590,945 | June 1, 2021 | May 31, 2026 | SHRESTA, SUJAN | reporter.nih.gov |
| Immune Pathophysiology of Sickle Cell Disease | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,589,657 | March 1, 2022 | December 31, 2028 | YAZDANBAKHSH, KARINA | reporter.nih.gov |
| Targeting undruggable RAS for cancer treatment | NIH | National Cancer Institute | 2021 to 2024 | $3,589,157 | September 1, 2018 | August 31, 2025 | DER, CHANNING J. | reporter.nih.gov |
| Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal | NIH | National Cancer Institute | 2021 to 2025 | $3,585,446 | July 1, 2010 | June 30, 2027 | NAKAGAWA, MAYUMI | reporter.nih.gov |
| Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,578,239 | February 1, 2018 | April 30, 2029 | DICK, THOMAS | reporter.nih.gov |
| Structure-Guided Design of Broadly Neutralizing Lassa Virus BiSpecific Antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,575,135 | December 24, 2018 | November 30, 2024 | BRANCO, LUIS MANUEL | reporter.nih.gov |
| Inhaled tigecycline therapy for pulmonary M. abscessus infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,573,339 | June 29, 2021 | May 31, 2027 | GONZALEZ-JUARRERO, MERCEDES | reporter.nih.gov |
| Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children | NIH | National Cancer Institute | 2021 to 2025 | $3,570,931 | August 5, 2021 | July 31, 2026 | BURRIDGE, PAUL W. | reporter.nih.gov |
| Targeted Cerebral Spinal Fluid (CSF) Drug Delivery - Enclear Precision System | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $3,564,917 | January 1, 2024 | December 31, 2026 | GLICKSMAN, MARCIE A | reporter.nih.gov |
| NCI Pediatric In Vivo Testing Program: Neuroblastoma | NIH | National Cancer Institute | 2021 to 2025 | $3,549,742 | July 1, 2021 | June 30, 2027 | MOSSE, YAEL P | reporter.nih.gov |
| Bioactive Metabolites Modulate Immune-Related Adverse Events in Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $3,549,010 | July 8, 2021 | February 28, 2027 | SHARMA, SONIA | reporter.nih.gov |
| Interactions between neutrophils and cholangiocytes in alcoholic hepatitis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $3,548,231 | September 25, 2021 | June 30, 2027 | NATHANSON, MICHAEL H | reporter.nih.gov |
| Chronic Wasting Disease Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,544,335 | July 8, 2021 | June 30, 2027 | MATHIASON, CANDACE K. | reporter.nih.gov |
| Preventing GVHD by inhibition of alloantigen presentation in the gut | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,543,040 | July 1, 2019 | June 30, 2027 | HILL, GEOFFREY ROGER | reporter.nih.gov |
| University of California and UT Southwestern D-PDTC | NIH | National Cancer Institute | 2023 to 2025 | $3,532,429 | August 1, 2023 | July 31, 2028 | CARVAJAL CARMONA, LUIS GUILLERMO | reporter.nih.gov |
| JAK-STAT Inhibition to Reduce Racial Disparities in Kidney Disease | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $3,524,489 | September 20, 2021 | May 31, 2027 | OLABISI, OPEYEMI AYODEJI | reporter.nih.gov |
| 1/2 Allogeneic Human Mesenchymal Stem Cell (MSC) Injection in Patients with Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,521,212 | September 15, 2020 | August 31, 2025 | BERGER, STUART | reporter.nih.gov |
| Evaluation of Clinical Outcome Assessment (COA) and Potential Biomarkers to Facilitate Interventional Trial for Mucopolysaccharidosis IIID Patients | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $3,519,934 | September 21, 2021 | August 31, 2025 | SINGAMSETTY, SRIKANTH | reporter.nih.gov |
| Acute/chronic limitations to transcriptional RNAi therapies for infectious and other liver diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,515,317 | August 1, 2006 | July 31, 2026 | KAY, MARK A | reporter.nih.gov |
| De Novo Design of Minibinder Antagonists for COVID-19 and Future Pandemics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,504,899 | August 2, 2021 | July 31, 2026 | BAKER, DAVID | reporter.nih.gov |
| Inducing durable, protective immune memory against malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,488,192 | January 16, 2019 | December 31, 2023 | KAPPE, STEFAN HI | reporter.nih.gov |
| Biochemical and cellular mechanisms linking actin mutations to visceral myopathy | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,487,348 | September 28, 2021 | August 31, 2027 | HEUCKEROTH, ROBERT O | reporter.nih.gov |
| Identifying Relapse Predictors and Therapeutic Vulnerabilities in Ph+ and Ph-like Acute Lymphoblastic Leukemia | NIH | National Cancer Institute | 2025 | $3,480,276 | August 1, 2025 | July 31, 2029 | LOH, MIGNON LEE-CHEUN | reporter.nih.gov |
| Development of a Clinical Hemoglobin Modulator | NIH | National Heart, Lung, and Blood Institute | 2021 to 2022 | $3,473,811 | June 1, 2020 | May 31, 2024 | PERRINE, SUSAN PARK | reporter.nih.gov |
| Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,469,861 | July 1, 2025 | June 30, 2028 | ROSENTHAL, PHILIP JON | reporter.nih.gov |
| Evaluation of Memory Responses and Biomarkers from a Phase IEnterotoxigenic Escherichia coli (ETEC) Intramuscular SubunitVaccine with dmLT Adjuvant | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,467,638 | September 24, 2021 | August 31, 2026 | NORTON, ELIZABETH B | reporter.nih.gov |
| Evolution of gliomas during treatment and resistance | NIH | National Cancer Institute | 2021 to 2025 | $3,464,231 | April 1, 2015 | June 30, 2026 | BEROUKHIM, RAMEEN | reporter.nih.gov |
| New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $3,453,304 | December 10, 2020 | November 30, 2025 | NEEL, BENJAMIN G. | reporter.nih.gov |
| A Vaccine for Lymphatic Filariasis, LFGuard™ | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,448,456 | March 1, 2019 | November 30, 2027 | CARTER, DARRICK ALBERT | reporter.nih.gov |
| Oncogenic mechanisms, molecular stratification and therapeutic targets of brain tumors | NIH | National Cancer Institute | 2022 to 2025 | $3,447,832 | September 24, 2021 | August 31, 2028 | IAVARONE, ANTONIO | reporter.nih.gov |
| Viral Gene Therapy for Menkes Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $3,444,962 | September 1, 2023 | June 30, 2027 | KALER, STEPHEN GERARD | reporter.nih.gov |
| Development of MecVax, a Cross Protective Subunit Vaccine for ETEC | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,440,502 | June 1, 2023 | May 31, 2028 | ZHANG, WEIPING | reporter.nih.gov |
| Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system | NIH | National Cancer Institute | 2021 to 2025 | $3,433,365 | July 1, 2021 | June 30, 2027 | BOTA, DANIELA ANNENELIE | reporter.nih.gov |
| Improving radiolabeled imaging and targeting of HER2 positive EG cancers using lovastatin | NIH | National Cancer Institute | 2021 to 2025 | $3,432,890 | December 1, 2020 | November 30, 2026 | LEWIS, JASON S. | reporter.nih.gov |
| Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohort | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $3,429,869 | September 30, 2021 | June 30, 2026 | FELDMAN, EVA LUCILLE | reporter.nih.gov |
| Characteristics of Botulinum Neurotoxins the Determine Potency | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,427,741 | January 18, 2019 | June 30, 2029 | PELLETT, SABINE | reporter.nih.gov |
| Unraveling yellow fever 17D vaccine attenuation: The role of type I interferon and innate immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,421,854 | February 15, 2016 | July 31, 2027 | RICE, CHARLES M | reporter.nih.gov |
| Tracking longitudinal change in presymptomatic genetic prion disease (TLC-Pre-gPrD) | NIH | National Institute on Aging | 2021 to 2023 | $3,419,291 | August 1, 2019 | May 31, 2025 | GESCHWIND, MICHAEL D | reporter.nih.gov |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING STUDY TO COMPARE THE SAFETY AND EFFICACY OF 3 DOSE LEVELS OF AV-1 IN HEALTHY ADULTS CHALLENGED WITH A CONTROLLED HUMAN INFECTION S | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $3,418,636 | August 23, 2023 | July 22, 2025 | DURBIN, ANNA PALMER | reporter.nih.gov |
| Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,410,042 | February 21, 2019 | January 31, 2025 | PERLIN, DAVID S | reporter.nih.gov |
| Contribution of RAN proteins to HD, SCA3 other CAG.CTG expansion diseases | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,408,902 | July 15, 2021 | June 30, 2027 | RANUM, LAURA P.W | reporter.nih.gov |
| Brain Glycogen-Metabolism,Mechanisms, and Therapeutic Potential | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $3,404,071 | May 15, 2020 | April 30, 2028 | GENTRY, MATTHEW S. | reporter.nih.gov |
| Chemogenomic Profiling of Plasmodium Falciparum Responses and Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,402,300 | February 10, 2015 | June 30, 2027 | ADAMS, JOHN H | reporter.nih.gov |
| Mycobacterium Tuberculosis (MTB) Quality Assessment Program (TBQA) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,397,377 | November 17, 2024 | November 16, 2025 | OLINGER, GENE GARRARD | reporter.nih.gov |
| Optimization and Modes of Action of NEU-4438, a New Anti-trypanosome Lead Drug | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,385,142 | August 19, 2016 | March 31, 2027 | MENSA-WILMOT, KOJO A. | reporter.nih.gov |
| Structure and function of the Plasmodium myosin XIV-actin glideosome. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,384,780 | May 11, 2017 | June 30, 2027 | TRYBUS, KATHLEEN M | reporter.nih.gov |
| Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,379,247 | August 1, 2019 | July 31, 2025 | GREENBERG, DAVID ELIHU | reporter.nih.gov |
| Regulation of Hemoglobin Switching | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,354,270 | August 5, 2013 | January 31, 2027 | BLOBEL, GERD A | reporter.nih.gov |
| Drug Discovery for Chagas Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,351,347 | May 9, 2019 | December 31, 2026 | BUCKNER, FREDERICK SIMMONS | reporter.nih.gov |
| Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance | NIH | National Cancer Institute | 2021 to 2025 | $3,350,719 | December 15, 2020 | November 30, 2025 | SHAH, NEIL P | reporter.nih.gov |
| AN INTEGRATED PLATFORM FOR NOVEL PERSONALIZED LIVER CANCER THERAPEUTICS | NIH | National Cancer Institute | 2021 to 2025 | $3,349,717 | July 1, 2021 | June 30, 2027 | GUCCIONE, ERNESTO | reporter.nih.gov |
| Dystrophin Replacement | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,349,499 | April 1, 1991 | April 30, 2026 | CHAMBERLAIN, JEFFREY S | reporter.nih.gov |
| Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment. | NIH | National Cancer Institute | 2021 to 2025 | $3,347,022 | July 1, 2021 | June 30, 2026 | MISCHEL, PAUL S | reporter.nih.gov |
| DNA-based Immune Phenotyping in HNSCC for Biomarkers of Response to Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $3,333,223 | January 1, 2021 | December 31, 2026 | KELSEY, KARL TIMOTHY | reporter.nih.gov |
| Targeting DKK-1 To Prevent Osteosarcoma Metastasis | NIH | National Cancer Institute | 2021 to 2025 | $3,331,390 | July 9, 2021 | June 30, 2026 | LOEB, DAVID M. | reporter.nih.gov |
| Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer) | NIH | National Cancer Institute | 2024 to 2025 | $3,329,707 | June 14, 2024 | May 31, 2027 | GOLDBERG, MANIJEH N | reporter.nih.gov |
| Cancer Immune-Interception for Lynch Syndrome | NIH | National Cancer Institute | 2021 to 2025 | $3,326,163 | September 21, 2021 | August 31, 2026 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| Real-time MRI-guided adaptive radiotherapy of unresectable pancreatic cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,323,920 | August 13, 2021 | July 31, 2026 | OTAZO, RICARDO | reporter.nih.gov |
| The impact of interstitial fluid flow on CAR T cell trafficking, distribution, and efficacy | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,320,824 | June 15, 2021 | March 31, 2027 | MUNSON, JENNIFER M | reporter.nih.gov |
| Second-Generation Novel Liver Stage Active Antimalarials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,320,110 | April 1, 2021 | March 31, 2027 | KELLY, JANE X | reporter.nih.gov |
| ncRNA: structure, function and inhibition | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,317,990 | April 1, 2018 | May 31, 2028 | VARANI, GABRIELE | reporter.nih.gov |
| Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,315,958 | January 1, 2019 | December 31, 2023 | AMBERG, SEAN M | reporter.nih.gov |
| Career Development in Pediatric and Medical Oncology | NIH | National Cancer Institute | 2021 to 2025 | $3,314,336 | September 30, 1997 | August 31, 2026 | MESHINCHI, SOHEIL | reporter.nih.gov |
| Defining the resistome in P. falciparum: evolution and mechanism | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,309,597 | November 2, 2022 | October 31, 2027 | WINZELER, ELIZABETH A | reporter.nih.gov |
| Bacteria and Host in TB Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,309,466 | April 10, 2020 | March 31, 2026 | ALLAND, DAVID | reporter.nih.gov |
| Targeted Delivery of Therapeutics into Motor Neurons for Post-exposure Treatment of Botulism | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,307,348 | August 1, 2021 | July 31, 2027 | DONG, MIN | reporter.nih.gov |
| Engineering AAV for safe and efficient gene delivery to the human retina | NIH | National Eye Institute | 2021 to 2025 | $3,303,996 | June 1, 2014 | June 30, 2029 | BOYE, SHANNON ELIZABETH | reporter.nih.gov |
| Genomics of Pulmonary Vascular Disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,302,250 | April 1, 2018 | March 31, 2025 | ALDRED, MICHEALA A | reporter.nih.gov |
| Lesion-centric optimization of multidrug therapies for tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,301,434 | January 15, 2020 | December 31, 2025 | ALDRIDGE, BREE BEARDSLEY | reporter.nih.gov |
| Transcriptional networks governing A. fumigatus virulence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,301,255 | September 22, 2021 | August 31, 2026 | FILLER, SCOTT G | reporter.nih.gov |
| The B7x pathways in the tumor microenvironment | NIH | National Cancer Institute | 2021 to 2025 | $3,299,614 | July 1, 2014 | November 30, 2026 | ZANG, XINGXING | reporter.nih.gov |
| Theranostics for Pediatric Brain Cancer | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,299,320 | April 15, 2021 | January 31, 2027 | DALDRUP-LINK, HEIKE ELIZABETH | reporter.nih.gov |
| Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas | NIH | National Cancer Institute | 2021 to 2025 | $3,294,656 | August 6, 2021 | July 31, 2026 | MACKALL, CRYSTAL | reporter.nih.gov |
| Small molecule-induced degradation of dengue proteins as an antiviral strategy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,293,894 | July 23, 2020 | June 30, 2025 | YANG, PRISCILLA LI-NING | reporter.nih.gov |
| FAST-FNA immune cell profiling in HNSCC | NIH | National Cancer Institute | 2021 to 2025 | $3,293,259 | January 26, 2021 | December 31, 2025 | WEISSLEDER, MD, PHD, RALPH | reporter.nih.gov |
| Once Bitten: Acquisition of Malaria Adaptive Immunity (OBAMA - Immunity) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,285,014 | July 1, 2025 | June 30, 2028 | PRUDHOMMEOMEARA, WENDY | reporter.nih.gov |
| Decoding innate immune signaling in normal and myelodysplastic hematopoiesis | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,283,833 | January 1, 2023 | December 31, 2029 | STARCZYNOWSKI, DANIEL | reporter.nih.gov |
| Multimodality Neuroimaging Evaluation of Cognitive Functioning in Lower Grade Astrocytoma | NIH | National Cancer Institute | 2022 to 2025 | $3,280,932 | September 9, 2022 | August 31, 2027 | LI, YAN | reporter.nih.gov |
| Leveraging Hyperpolarized MRI for Precision Oncology Approaches in Head and Neck Cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,278,152 | September 1, 2022 | August 31, 2028 | LAI, STEPHEN Y | reporter.nih.gov |
| Stable therapy in Pompe disease through genome editing | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,274,213 | August 1, 2021 | July 31, 2026 | KOEBERL, DWIGHT D | reporter.nih.gov |
| Advanced Development of a Combined Shigella-ETEC Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,267,570 | June 9, 2023 | May 31, 2028 | BARRY, EILEEN M. | reporter.nih.gov |
| Informing Drug Synergy: Investigating Mycobacterial Membrane Protein Structure and Function | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,262,539 | August 1, 2025 | July 31, 2029 | REGO, ELIZABETH HESPER | reporter.nih.gov |
| Drugging EBNA1 to Treat EBV-Associated Cancers | NIH | National Cancer Institute | 2021 to 2025 | $3,259,551 | June 15, 2021 | May 31, 2026 | MESSICK, TROY E | reporter.nih.gov |
| Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,255,352 | September 16, 2020 | August 31, 2025 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,252,105 | April 1, 2022 | August 31, 2027 | POWELL, DANIEL J. | reporter.nih.gov |
| Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,249,590 | March 10, 2020 | February 28, 2026 | SHERMAN, DAVID R | reporter.nih.gov |
| A Phase 1b Study of Inhaled CO for the Treatment of Sepsis-Induced ARDS | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $3,249,318 | September 15, 2020 | April 30, 2025 | PLATAKI, MARIA | reporter.nih.gov |
| Human Monoclonal Antibodies for Encephalitic Alphaviruses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,248,015 | July 20, 2022 | June 30, 2027 | CROWE, JAMES E | reporter.nih.gov |
| SCD REVIVE - Retina to Evaluate Vaso occlusion In the Vasculature of the Eye | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,242,672 | April 10, 2022 | March 31, 2027 | GLASSBERG, JEFFREY AVINS | reporter.nih.gov |
| Mycobacterial Lung Diseases in Virginia: sequencing and clinical determinants of relapse and outcome | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,237,702 | January 1, 2021 | December 31, 2026 | HOUPT, ERIC R | reporter.nih.gov |
| Multi-Targeting Oligonucleotide Therapeutics for Familial and Sporadic Amyotrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,236,744 | May 15, 2019 | May 31, 2029 | WATTS, JONATHAN K | reporter.nih.gov |
| Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients | NIH | National Cancer Institute | 2021 to 2025 | $3,235,983 | July 1, 2020 | June 30, 2027 | LAROCCA, CECILIA | reporter.nih.gov |
| 2/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy for Pediatric Pulmonary Arterial Hypertension-DCC | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,234,679 | September 15, 2021 | November 30, 2026 | CHAKRABORTY, HRISHIKESH | reporter.nih.gov |
| Genetic and Structural Basis for Virus Neutralization of Paramyxoviruses | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,230,785 | September 16, 2024 | September 15, 2027 | reporter.nih.gov | |
| Spectinomycin analogs for NTM infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,229,019 | September 17, 2020 | August 31, 2025 | LEE, RICHARD E. | reporter.nih.gov |
| Novel Methods to Inform HIV/TB Clinical Trial Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,228,180 | September 1, 2011 | August 31, 2025 | REDDY, KRISHNA P | reporter.nih.gov |
| Imaging Modulation of Immune Phenotype | NIH | National Cancer Institute | 2021 to 2025 | $3,227,270 | February 1, 2021 | January 31, 2027 | FERRARA, KATHERINE W | reporter.nih.gov |
| Developing second generation SCID pig models: filling the gaps to improve translation of therapeutics in regenerative medicine | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $3,219,338 | February 15, 2020 | July 31, 2029 | TUGGLE, CHRISTOPHER | reporter.nih.gov |
| Protecting colonic mucus to mitigate acute intestinal graft-versus-host disease | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,218,917 | August 15, 2015 | June 30, 2026 | JENQ, ROBERT | reporter.nih.gov |
| Addressing Chemoresistance in Pancreatic and Ovarian Cancers: Photodynamic Priming and Repurposing of Tetracyclines using Targeted Photo-Activable Multi-Inhibitor Liposome | NIH | National Cancer Institute | 2021 to 2025 | $3,218,280 | April 1, 2021 | March 31, 2027 | HUANG, HUANG CHIAO | reporter.nih.gov |
| Circulating Genomic Determinants of Treatment Failure in Hodgkin Lymphoma | NIH | National Cancer Institute | 2021 to 2025 | $3,211,729 | March 4, 2021 | February 28, 2026 | ALIZADEH, ASH ARASH | reporter.nih.gov |
| Mitochondrial respiratory chain disease mechanistic and therapeutic modeling | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,211,520 | March 1, 2020 | July 31, 2030 | FALK, MARNI J | reporter.nih.gov |
| Mycobacterium avium complex pulmonary infection: immunologic and transcriptomic signatures of disease and treatment response | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,209,026 | August 20, 2024 | July 31, 2028 | WINTHROP, KEVIN LORING | reporter.nih.gov |
| Outcomes for CLL patients treated with novel therapy | NIH | National Cancer Institute | 2021 to 2025 | $3,205,518 | September 15, 2021 | August 31, 2026 | KAY, NEIL E | reporter.nih.gov |
| Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,203,991 | July 13, 2020 | July 31, 2027 | KLAUSNER, JEFFREY DAVID | reporter.nih.gov |
| Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias | NIH | National Cancer Institute | 2022 to 2025 | $3,200,543 | May 1, 2022 | April 30, 2027 | JIN, JIAN | reporter.nih.gov |
| Development of a Chimeric Syphilis Vaccine Candidate to Combat Local, Disseminated and Congenital Syphilis Infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,194,893 | April 15, 2024 | March 31, 2029 | CAMERON, CAROLINE E | reporter.nih.gov |
| Dual Targeting of Mtb Resistance Mechanisms | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,194,513 | September 22, 2020 | August 31, 2025 | GRUNDNER, CHRISTOPH | reporter.nih.gov |
| Chaperone Dysfunction in Myopathy: Connecting Yeast Genetics with Mouse Models | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,193,112 | August 1, 2015 | June 30, 2027 | TRUE-KROB, HEATHER L | reporter.nih.gov |
| Islet Dysregulation in Infants with Congenital Hyperinsulinism | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $3,192,917 | August 15, 1999 | June 30, 2025 | DE LEON, DIVA D. | reporter.nih.gov |
| Immunomodulation in AAV gene therapy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,192,404 | August 21, 2025 | July 31, 2029 | ASOKAN, ARAVIND | reporter.nih.gov |
| Co-Clinical Research Resource for Imaging Tumor Associated Macrophages | NIH | National Cancer Institute | 2021 to 2025 | $3,191,659 | September 15, 2021 | August 31, 2026 | DALDRUP-LINK, HEIKE ELIZABETH | reporter.nih.gov |
| Impact of ocular microbiome, immune response and Chlamydiae on trachoma following MDA | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,190,228 | July 1, 2022 | June 30, 2027 | DEAN, DEBORAH ANNE | reporter.nih.gov |
| Collaborative Integration of HCV Molecular Virology and Mathematical Modeling | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,185,361 | August 1, 2010 | May 31, 2027 | UPRICHARD, SUSAN L. | reporter.nih.gov |
| Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model | NIH | National Cancer Institute | 2021 to 2025 | $3,179,936 | September 8, 2021 | August 31, 2027 | DAHIA, PATRICIA LEAL | reporter.nih.gov |
| In vivo endobronchial OCT for IPF diagnosis and therapy response assessment | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $3,179,658 | June 1, 2020 | May 31, 2026 | HARIRI, LIDA P | reporter.nih.gov |
| Peripherally-restricted non-addictive cannabinoids for cancer pain treatment | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $3,174,343 | August 1, 2023 | July 31, 2025 | SPIGELMAN, IGOR | reporter.nih.gov |
| Impact of gene-drive systems for population modification on malaria vector mosquitoes | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,173,474 | June 9, 2023 | May 31, 2026 | JAMES, ANTHONY A. | reporter.nih.gov |
| Drug eluting injectable biomaterials for next generation chemoembolization | NIH | National Cancer Institute | 2021 to 2025 | $3,173,416 | May 1, 2021 | April 30, 2027 | OKLU, RAHMI | reporter.nih.gov |
| Biomarker Signatures of TB Infection in Young Children With and Without HIV | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,173,148 | April 28, 2023 | March 31, 2028 | SALGAME, PADMINI | reporter.nih.gov |
| Preclinical modeling to study Tuberculous Meningitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,172,738 | April 1, 2020 | March 31, 2026 | JAIN, SANJAY | reporter.nih.gov |
| 1/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy In Pediatric Pulmonary Arterial Hypertension | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $3,169,398 | September 15, 2021 | May 31, 2026 | ROMER, LEWIS H | reporter.nih.gov |
| A Patient-Centric Approach to Advance Functional Precision Oncology | NIH | National Cancer Institute | 2023 to 2025 | $3,167,628 | September 22, 2023 | August 31, 2028 | KEMP, CHRISTOPHER J | reporter.nih.gov |
| Rational development of a vaccine against tick-borne rickettsioses | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,166,318 | August 1, 2022 | July 31, 2027 | FANG, RONG MEGAN | reporter.nih.gov |
| Intrarenal B cells in acute kidney allograft rejection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,165,260 | February 15, 2020 | January 31, 2026 | CHONG, ANITA S | reporter.nih.gov |
| Advancing Targeted Therapies for Cushing's Disease Using Pituitary Neuroendocrine Tumor Organoids | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $3,162,826 | September 12, 2025 | August 31, 2029 | ZAVROS, YANA | reporter.nih.gov |
| IND-enabling studies of non-immunogenic gene therapy for ultra-rare DMD patients excluded from dystrophin trials | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $3,161,261 | August 1, 2024 | July 31, 2027 | STEDMAN, HANSELL H | reporter.nih.gov |
| Magnetic Resonance Fingerprinting of Glutamate Metabolism for Guiding Glioma Cancer Care | NIH | National Cancer Institute | 2025 | $3,155,815 | August 14, 2025 | July 31, 2029 | PAECH, DANIEL | reporter.nih.gov |
| Spatial functional genomics to identify regulators of the tumor microenvironment and cancer immunity | NIH | National Cancer Institute | 2023 to 2025 | $3,154,814 | September 19, 2023 | August 31, 2028 | BROWN, BRIAN D | reporter.nih.gov |
| Risk stratification in pulmonary arterial hypertension: Intersection of OMICs and longitudinal phenotypes through the PAH Biobank | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,154,051 | September 1, 2022 | June 30, 2026 | NICHOLS, WILLIAM C | reporter.nih.gov |
| Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,153,883 | September 24, 2018 | October 31, 2028 | HEYSELL, SCOTT K | reporter.nih.gov |
| Dynamics and mechanisms of filovirus envelop glycoproteins | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,151,198 | September 19, 2022 | July 31, 2027 | MUNRO, JAMES B | reporter.nih.gov |
| Macrophage senescence as a driver of granuloma failure and progression to necrosis in TB and TB/HIV | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,145,850 | September 19, 2025 | August 31, 2029 | BISHAI, WILLIAM RAMSES | reporter.nih.gov |
| Plasmodium Protein Kinase Focused Antimalarials Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,144,589 | July 11, 2022 | June 30, 2027 | CHAKRABARTI, DEBOPAM | reporter.nih.gov |
| Targeting Pediatric Cancer Vulnerabilities | NIH | National Cancer Institute | 2023 to 2025 | $3,144,539 | September 19, 2023 | August 31, 2030 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| Discovery of Phospopantetheinyl Transferse Inhibitors Against Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,136,573 | July 13, 2021 | June 30, 2025 | AUBE, JEFFREY | reporter.nih.gov |
| Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,135,970 | February 1, 2019 | January 31, 2029 | DIEHL, SEAN A. | reporter.nih.gov |
| Shigella Conjugate Vaccine (SCV4) Development, Characterization, and Pre-clinical Evaluation | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,134,727 | June 23, 2023 | May 31, 2028 | RYAN, EDWARD T. | reporter.nih.gov |
| Integration and interoperability of complex data and tissues from the human brain | NIH | National Center for Advancing Translational Sciences | 2023 to 2025 | $3,131,401 | September 20, 2023 | December 31, 2026 | LOEB, JEFFREY A | reporter.nih.gov |
| Iron independent role for yersiniabactin in Yersinia pestis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,128,137 | June 4, 2021 | May 31, 2027 | LAWRENZ, MATTHEW B | reporter.nih.gov |
| Culturally adapted mobile treatment of chronic pain in adolescent survivors of pediatric bone sarcoma | NIH | National Cancer Institute | 2025 | $3,128,074 | September 20, 2022 | May 31, 2028 | BRINKMAN, TARA M | reporter.nih.gov |
| A Novel RNA Therapeutics Platform to Treat Facioscapulohumeral Muscular Dystrophy and other Neuromuscular Disorders | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,123,687 | September 20, 2021 | August 31, 2027 | SALEH, ANTHONY D | reporter.nih.gov |
| Multi-scale modeling of glioma for the prediction of treatment response, treatment monitoring and treatment allocation | NIH | National Cancer Institute | 2021 to 2025 | $3,120,699 | May 1, 2021 | April 30, 2027 | GEVAERT, OLIVIER | reporter.nih.gov |
| Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,119,133 | January 1, 2021 | December 31, 2026 | YOON, HARRY H | reporter.nih.gov |
| Penetrating the “Black box”: Prediction of early Bronchiolitis obliterans in Pediatric Hematopoietic Stem Cell Transplant Recipients | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,117,523 | July 15, 2021 | April 30, 2027 | MYERS, KASIANI | reporter.nih.gov |
| Small molecule enhancers of tumor immunity targeting the LPA5 GPCR | NIH | National Cancer Institute | 2022 to 2025 | $3,114,085 | August 1, 2022 | July 31, 2026 | TIGYI, GABOR J | reporter.nih.gov |
| Targeting CDK6 expression/activity in Ph+ and Ph1-like acute lymphoblastic leukemia (ALL) | NIH | National Cancer Institute | 2021 to 2025 | $3,113,868 | July 1, 2021 | June 30, 2027 | CALABRETTA, BRUNO | reporter.nih.gov |
| PROTECT (Harnessing PROTEin degradation for Advanced Childhood Tumors) | NIH | National Cancer Institute | 2024 to 2025 | $3,108,431 | May 1, 2024 | April 30, 2026 | STEGMAIER, KIMBERLY | reporter.nih.gov |
| Mechanisms of the Development and Maintenance of Salmonella Gallbladder Carriage | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,105,141 | June 1, 2015 | April 30, 2027 | GUNN, JOHN S | reporter.nih.gov |
| Crosstalk Between Lipid Droplets and Other Organelles in Podocytes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,102,617 | September 5, 2025 | September 4, 2029 | FORNONI, ALESSIA | reporter.nih.gov |
| FEND-TB | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,089,360 | September 10, 2025 | August 31, 2030 | ELLNER, JERROLD J. | reporter.nih.gov |
| EXTENSION OF ESCUDDO FOLLOW-UP FROM FIVE YEARS TO 7.5 YEARS (REFERRED TO AS ESCUDDO-7) | NIH | National Cancer Institute | 2025 | $3,083,060 | March 26, 2025 | September 15, 2025 | reporter.nih.gov | |
| Immunological characterization of rationally-designed vaccines against plague in mice and non-human primate models | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,082,735 | February 1, 2021 | July 31, 2026 | CHOPRA, ASHOK K | reporter.nih.gov |
| Optimizing lipid RVn monophosphate prodrugs to maximize RVn-triphosphate delivery | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,082,513 | July 18, 2025 | June 30, 2029 | CARLIN, AARON F. | reporter.nih.gov |
| Privileged and primitive hematopoietic stem cells, niches, and regulatory T cells | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $3,081,005 | December 1, 2021 | November 30, 2025 | FUJISAKI, JOJI | reporter.nih.gov |
| Novel Therapeutics to Target Parasite Cytochrome bc1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,077,845 | July 15, 2012 | June 30, 2027 | RISCOE, MICHAEL KEVIN | reporter.nih.gov |
| Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST) | NIH | National Cancer Institute | 2021 to 2025 | $3,076,366 | April 1, 2021 | March 31, 2026 | CHI, PING | reporter.nih.gov |
| Investigating Cardiac Ion Channels by Novel Methods | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $3,076,196 | June 5, 2021 | May 31, 2029 | MARX, STEVEN O | reporter.nih.gov |
| Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $3,074,708 | March 15, 2020 | February 28, 2025 | BLAIR, IAN ALEXANDER | reporter.nih.gov |
| Molecular basis of antimalarial drug resistance in Plasmodium vivax | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,064,807 | March 18, 2022 | February 28, 2027 | DURAISINGH, MANOJ T | reporter.nih.gov |
| The Role of the Gut Microbiome and Short Chain Fatty Acids in the Regulation of Inflammation and Neuropsychological Symptoms in Patients with Head and Neck Cancer | NIH | National Institute of Nursing Research | 2022 to 2025 | $3,064,029 | May 9, 2022 | February 28, 2027 | XIAO, CANHUA | reporter.nih.gov |
| Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistance | NIH | National Cancer Institute | 2021 to 2025 | $3,062,772 | September 22, 2021 | August 31, 2026 | MUNN, LANCE L. | reporter.nih.gov |
| Sulfated Non-Anticoagulant Heparin Nanoparticle (VVP728) for Sickle Cell Disease Management | NIH | National Heart, Lung, and Blood Institute | 2022 to 2024 | $3,058,782 | September 23, 2019 | June 30, 2026 | KORCZAK, BOZENA | reporter.nih.gov |
| Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,050,000 | July 20, 2020 | March 31, 2027 | MCDONNELL, MARK E | reporter.nih.gov |
| Structure and functional mechanisms of molecular chaperones and protein kinases | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,046,637 | May 1, 2017 | January 31, 2028 | KALODIMOS, CHARALAMPOS | reporter.nih.gov |
| Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,045,306 | June 1, 2018 | March 31, 2025 | HARTY, RONALD N | reporter.nih.gov |
| Therapeutic Targeting Mitochondrial C1 Metabolism | NIH | National Cancer Institute | 2021 to 2025 | $3,043,890 | January 1, 2021 | December 31, 2026 | MATHERLY, LARRY H | reporter.nih.gov |
| Integrating Chemistry and Evolution to Illuminate Biology and Enable Novel Therapeutics | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,043,617 | May 1, 2016 | April 30, 2027 | LIU, DAVID R | reporter.nih.gov |
| Assembly and export of mycobacterial lipoglycans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,040,802 | June 10, 2021 | May 31, 2027 | JACKSON, MARY | reporter.nih.gov |
| Early Detection of Transthyretin Cardiac Amyloidosis: Defining a Novel Target for HFpEF Treatment and Prevention in Late Life | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $3,039,615 | March 1, 2020 | January 31, 2026 | DORBALA, SHARMILA | reporter.nih.gov |
| Systems biological assessment of vaccination-induced protective immunity in African children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,037,984 | February 1, 2022 | January 31, 2027 | PULENDRAN, BALI | reporter.nih.gov |
| Enhancing cytotoxic lymphocytes in a TB vaccine strategy | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,037,076 | February 25, 2022 | January 31, 2027 | FLYNN, JOANNE L. | reporter.nih.gov |
| Development of an ophthalmic diagnostic probe for cerebral amyloid angiopathy in patients | NIH | National Institute on Aging | 2021 to 2022 | $3,033,670 | June 1, 2021 | May 31, 2024 | SARRAF, STELLA | reporter.nih.gov |
| Molecular Genetic Insight into Neurodegenerative Disease from Drosophila | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $3,032,672 | December 1, 2016 | November 30, 2025 | BONINI, NANCY M | reporter.nih.gov |
| Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,027,518 | March 17, 2020 | February 28, 2025 | KARAKOUSIS, PETROS C | reporter.nih.gov |
| Dynamic 3D chromatin remodeling in acute leukemia - Resubmission - 1 | NIH | National Cancer Institute | 2021 to 2025 | $3,027,488 | April 1, 2021 | June 30, 2026 | TSIRIGOS, ARISTOTELIS | reporter.nih.gov |
| Mitigation of Radiation Induced Gastrointestinal Syndrome. | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,026,290 | August 1, 2023 | July 31, 2026 | NORRIS, ANDREW JOHN | reporter.nih.gov |
| Novel Antimalarials from Fungi | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,025,049 | May 18, 2020 | April 30, 2026 | CHAKRABARTI, DEBOPAM | reporter.nih.gov |
| Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,024,535 | July 1, 2020 | June 30, 2025 | JAIN, SANJAY | reporter.nih.gov |
| Providing ethical guidance for the development of individualized genomic medicine as rare as n-of-1 | NIH | National Human Genome Research Institute | 2022 to 2025 | $3,020,238 | September 1, 2022 | June 30, 2026 | YU, TIMOTHY WEI-WEN | reporter.nih.gov |
| Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV | NIH | National Cancer Institute | 2022 to 2025 | $3,019,287 | September 12, 2022 | August 31, 2027 | BHADURI-MCINTOSH, SUMITA | reporter.nih.gov |
| Trial Readiness and Endpoint Assessment in LGMDR1 (TREATing-LGMDR1) | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $3,017,334 | April 15, 2023 | March 31, 2028 | JOHNSON, NICHOLAS ELWOOD | reporter.nih.gov |
| Analysis of Chemical Structures and Therapeutic Activity of Agents for HIV, TB, and HBV (CHEMDB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,016,918 | September 30, 2024 | September 29, 2025 | SUMNER, LOUISE | reporter.nih.gov |
| Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,015,759 | May 1, 2020 | May 31, 2026 | REITZ, ALLEN BERNARD | reporter.nih.gov |
| Development of next generation 2HG and metabolic MR imaging for precision oncology of mutant IDH and wildtype glioma patients | NIH | National Cancer Institute | 2021 to 2025 | $3,009,508 | February 1, 2021 | January 31, 2027 | ANDRONESI, OVIDIU C | reporter.nih.gov |
| DCTD Cancer Imaging | NIH | National Cancer Institute | 2021 to 2024 | $3,009,076 | September 26, 2008 | August 30, 2019 | HEIMBROOK, DAVID | reporter.nih.gov |
| Respiratory Virus Vaccine and Adjuvant Exploration | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | April 19, 2019 | March 31, 2025 | BARIC, RALPH S | reporter.nih.gov |
| A Unique Automated Bioreactor for Rearing Aseptic Mosquitoes from Larvae to Adults to Support Manufacture of Sanaria PfSPZ Products | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | July 18, 2018 | March 31, 2025 | BILLINGSLEY, PETER F. | reporter.nih.gov |
| Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | May 24, 2021 | April 30, 2025 | COBURN, GLEN ANDREW | reporter.nih.gov |
| Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,000,000 | August 1, 2017 | March 31, 2026 | PANG, XIAOWU | reporter.nih.gov |
| BRITE-Eye: An integrated discovery engine for CNS therapeutic targets driven by high throughput genetic screens, functional readouts in human neurons, and machine learning | NIH | National Institute of Mental Health | 2023 to 2024 | $2,999,997 | September 19, 2023 | August 31, 2025 | WILLIAMS, LUIS ALBERTO | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of California Los Angeles | Los Angeles, CA | 69 | $577.7 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 66 | $523.1 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 176 | $278.5 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 170 | $267.1 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 155 | $242.2 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 129 | $219.7 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 154 | $197 million | 0 | $0 |
| Public Health Institute | Oakland, CA | 5 | $185.7 million | 0 | $0 |
| Stanford University | Stanford, CA | 147 | $185.4 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 100 | $169.9 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 47 | $162.2 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 108 | $152.1 million | 0 | $0 |
| Washington University | Saint Louis, MO | 144 | $149.8 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 132 | $143.9 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 103 | $143.8 million | 0 | $0 |
| Emory University | Atlanta, GA | 98 | $141.8 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 121 | $135 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 71 | $133.7 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 59 | $130.8 million | 0 | $0 |
| Yale University | New Haven, CT | 90 | $126.8 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 76 | $123.7 million | 0 | $0 |
| University of Washington | Seattle, WA | 66 | $109.9 million | 0 | $0 |
| Sloan-Kettering Inst Can Research | New York, NY | 76 | $109.8 million | 0 | $0 |
| Duke University | Durham, NC | 95 | $109.7 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 71 | $98.8 million | 0 | $0 |
| Ohio State University | Columbus, OH | 73 | $97.7 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 89 | $96.3 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 74 | $93.6 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 43 | $92.7 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 67 | $88.1 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 81 | $87.9 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 86 | $87.6 million | 0 | $0 |
| University of Florida | Gainesville, FL | 76 | $86.8 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 65 | $86.3 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 55 | $83.4 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 48 | $81.9 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 74 | $81.5 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 70 | $80.3 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 49 | $74.2 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 61 | $73.3 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 54 | $69.2 million | 0 | $0 |
| University of Chicago | Chicago, IL | 36 | $69 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 66 | $67.8 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 47 | $67.1 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 51 | $65.4 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 29 | $64.8 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 46 | $59.7 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 40 | $59.4 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 16 | $55.5 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 45 | $54.6 million | 0 | $0 |
| NRG Oncology Foundation, Inc. | Philadelphia, PA | 1 | $54.3 million | 0 | $0 |
| ST. Joseph's Hospital and Medical Center | Phoenix, AZ | 3 | $52.7 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 38 | $50.8 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 53 | $50.1 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 63 | $49.7 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 42 | $47.5 million | 0 | $0 |
| University of California at Davis | Davis, CA | 45 | $44.7 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 42 | $43.7 million | 0 | $0 |
| Research Inst Nationwide Children's Hosp | Columbus, OH | 29 | $42.9 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 38 | $42.6 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 26 | $42.5 million | 0 | $0 |
| H. Lee Moffitt Cancer CTR & Res Inst | Tampa, FL | 37 | $40.5 million | 0 | $0 |
| Sanaria, Inc. | Rockville, MD | 19 | $39.2 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 35 | $38.1 million | 0 | $0 |
| University of Rochester | Rochester, NY | 26 | $37.4 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 33 | $37 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 35 | $33.8 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 16 | $33.7 million | 0 | $0 |
| Children's Research Institute | Washington, DC | 26 | $33.3 million | 0 | $0 |
| Fundacion Inciensa | San Jose | 2 | $32.6 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 9 | $31.7 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 23 | $31.7 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 25 | $31.6 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 12 | $31.6 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 19 | $31.4 million | 0 | $0 |
| Battelle Memorial Institute | Columbus, OH | 3 | $31.4 million | 0 | $0 |
| Midwest Research Institute | Kansas City, MO | 4 | $31.3 million | 0 | $0 |
| Broad Institute, Inc. | Cambridge, MA | 20 | $31.1 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 25 | $30.8 million | 0 | $0 |
| Medical College of Wisconsin | Milwaukee, WI | 22 | $30.4 million | 0 | $0 |
| Mayo Clinic Jacksonville | Jacksonville, FL | 19 | $30.2 million | 0 | $0 |
| Louisiana State University | Baton Rouge, LA | 2 | $30.1 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 24 | $30.1 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 8 | $29.8 million | 0 | $0 |
| Colorado State University | Fort Collins, CO | 23 | $29.7 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 34 | $28.6 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 15 | $28.4 million | 0 | $0 |
| Hackensack University Medical Center | Hackensack, NJ | 11 | $27.8 million | 0 | $0 |
| Wits Health Consortium (pty), LTD | Parktown | 3 | $27.6 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 12 | $27.3 million | 0 | $0 |
| Brown University | Providence, RI | 18 | $26.9 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 35 | $26.7 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 31 | $26.5 million | 0 | $0 |
| Beth Israel Deaconess Medical Center | Boston, MA | 21 | $26 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 23 | $25.7 million | 0 | $0 |
| Jackson Laboratory | Bar Harbor, ME | 10 | $25.6 million | 0 | $0 |
| George Washington University | Washington, DC | 22 | $25.3 million | 0 | $0 |
| Georgetown University | Washington, DC | 16 | $24.8 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 24 | $24.1 million | 0 | $0 |
| Roswell Park Cancer Institute Corp | Buffalo, NY | 19 | $23.4 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 3,411 | $2,316,648,895 | 0 | $0 |
| 2024 | 3,552 | $2,189,847,218 | 0 | $0 |
| 2023 | 3,507 | $2,219,315,276 | 0 | $0 |
| 2022 | 3,501 | $2,256,717,022 | 0 | $0 |
| 2021 | 3,435 | $2,004,808,205 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 62 awards here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) | PA-24-182 | NIH | May 8, 2027 | Not listed | Notice number printed on 11 awards here | |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 10 awards here | |
| NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed) | PA-25-080 | NIH | September 7, 2027 | Not listed | Notice number printed on 5 awards here | |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | May 7, 2027 | Not listed | Notice number printed on 4 awards here | |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed) | PA-24-188 | NIH | May 7, 2027 | Not listed | Notice number printed on 2 awards here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Required) | PA-24-181 | NIH | May 8, 2027 | Not listed | Notice number printed on 1 award here | |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Required) | PA-24-184 | NIH | May 8, 2027 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 1,471 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 1,471 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 1,471 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 1,471 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 1,471 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 1,471 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,471 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,471 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,471 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,471 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,471 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.